Please sign in to follow a disease.
Epithelial neoplasm
MONDO:0005626A benign or malignant neoplasm that arises from and is composed of epithelial cells. This category include adenomas, papillomas, and carcinomas.
Also known as: epithelial neoplasm, epithelioma
16008 clinical trials for this condition and its sub-types, 22 tagged with Epithelial neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Epithelial neoplasm
-
Carcinoma 224 trials · 14,724 incl. sub-types
49 sub-types
- Adenocarcinoma 184 trials · 5,243 incl. sub-types Sub-types →
- Digestive system carcinoma 25 trials · 4,876 incl. sub-types Sub-types →
- Lung carcinoma 137 trials · 3,320 incl. sub-types Sub-types →
- Breast carcinoma 665 trials · 2,688 incl. sub-types Sub-types →
- Squamous cell carcinoma 177 trials · 1,766 incl. sub-types Sub-types →
- Head and neck carcinoma 73 trials · 1,415 incl. sub-types Sub-types →
- Prostate carcinoma 394 trials · 1,321 incl. sub-types Sub-types →
- Renal carcinoma 85 trials · 764 incl. sub-types Sub-types →
- Neuroendocrine carcinoma 106 trials · 744 incl. sub-types Sub-types →
- Transitional cell carcinoma 249 trials · 721 incl. sub-types Sub-types →
- Urinary bladder carcinoma 392 trials · 669 incl. sub-types Sub-types →
- Malignant epithelial tumor of ovary 8 trials · 656 incl. sub-types Sub-types →
- Uterine carcinoma 3 trials · 611 incl. sub-types Sub-types →
- Invasive carcinoma 4 trials · 604 incl. sub-types Sub-types →
- Peritoneal carcinoma 16 trials · 389 incl. sub-types Sub-types →
- In situ carcinoma 25 trials · 318 incl. sub-types Sub-types →
- Skin carcinoma 34 trials · 281 incl. sub-types Sub-types →
- Thyroid gland carcinoma 41 trials · 237 incl. sub-types Sub-types →
- Fallopian tube carcinoma 126 trials · 182 incl. sub-types Sub-types →
- Secondary carcinoma 1 trial · 169 incl. sub-types Sub-types →
- Bone carcinoma 0 trials · 131 incl. sub-types Sub-types →
- Basal cell carcinoma 111 trials · 120 incl. sub-types Sub-types →
- Laryngeal carcinoma 56 trials · 114 incl. sub-types Sub-types →
- Papillary carcinoma 8 trials · 112 incl. sub-types Sub-types →
- Large cell carcinoma 2 trials · 87 incl. sub-types Sub-types →
- Undifferentiated carcinoma 6 trials · 80 incl. sub-types Sub-types →
- Mucin-producing carcinoma 0 trials · 58 incl. sub-types Sub-types →
- Retroperitoneum carcinoma 0 trials · 52 incl. sub-types Sub-types →
- Vulvar carcinoma 24 trials · 45 incl. sub-types Sub-types →
- Thymic carcinoma 41 trials · 44 incl. sub-types Sub-types →
- Penile carcinoma 9 trials · 35 incl. sub-types Sub-types →
- Sarcomatoid carcinoma 1 trial · 26 incl. sub-types Sub-types →
- Vaginal carcinoma 12 trials · 22 incl. sub-types Sub-types →
- Carcinoma of urethra 2 trials · 21 incl. sub-types Sub-types →
- Ureter carcinoma 1 trial · 19 incl. sub-types Sub-types →
- Choroid plexus carcinoma 11 trials Sub-types →
- Basaloid carcinoma 0 trials · 5 incl. sub-types Sub-types →
- Cribriform carcinoma 1 trial · 4 incl. sub-types Sub-types →
- Combined carcinoid and adenocarcinoma 0 trials · 2 incl. sub-types Sub-types →
- Malignant myoepithelioma 2 trials Sub-types →
- Carcinoma ex pleomorphic adenoma 1 trial Sub-types →
- Scrotal carcinoma 0 trials · 1 incl. sub-types Sub-types →
- Trachea carcinoma 1 trial Sub-types →
- Krebs 2 carcinoma 0 trials
- Comedocarcinoma 0 trials
- Epithelial-myoepithelial carcinoma 0 trials Sub-types →
- Glycogen-rich carcinoma 0 trials Sub-types →
- Lipid-rich carcinoma 0 trials Sub-types →
- Lymph node carcinoma 0 trials
-
Glandular cell neoplasm 6 trials · 5,266 incl. sub-types
10 sub-types
- Adenocarcinoma 184 trials · 5,243 incl. sub-types Sub-types →
- Serous neoplasm 0 trials · 207 incl. sub-types Sub-types →
- Mucinous neoplasm 1 trial · 71 incl. sub-types Sub-types →
- Cystadenoma 0 trials · 11 incl. sub-types Sub-types →
- Oncocytic neoplasm 0 trials · 7 incl. sub-types Sub-types →
- Vaginal glandular neoplasm 0 trials · 7 incl. sub-types Sub-types →
- Vulvar glandular neoplasm 0 trials · 5 incl. sub-types Sub-types →
- Villous adenoma 0 trials · 2 incl. sub-types Sub-types →
- Glandular papilloma 0 trials Sub-types →
- Rete ovarii adenoma 0 trials Sub-types →
-
Squamous cell neoplasm 21 trials · 1,836 incl. sub-types
7 sub-types
- Squamous cell carcinoma 177 trials · 1,766 incl. sub-types Sub-types →
- Squamous cell intraepithelial neoplasia 26 trials · 43 incl. sub-types Sub-types →
- Craniopharyngioma 29 trials Sub-types →
- Vulvar squamous neoplasm 0 trials · 28 incl. sub-types Sub-types →
- Vaginal squamous tumor 0 trials · 8 incl. sub-types Sub-types →
- Ovarian squamous cell neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Ocular surface squamous neoplasia 1 trial
-
Transitional cell neoplasm 0 trials · 699 incl. sub-types
2 sub-types
- Urothelial neoplasm 2 trials · 693 incl. sub-types Sub-types →
- Brenner tumor 6 trials Sub-types →
-
Ovarian epithelial tumor 14 trials · 664 incl. sub-types
11 sub-types
- Malignant epithelial tumor of ovary 8 trials · 656 incl. sub-types Sub-types →
- Ovarian serous tumor 6 trials · 207 incl. sub-types Sub-types →
- Ovarian clear cell tumor 7 trials · 57 incl. sub-types Sub-types →
- Borderline epithelial tumor of ovary 6 trials · 16 incl. sub-types Sub-types →
- Ovarian mucinous neoplasm 1 trial · 16 incl. sub-types Sub-types →
- Ovarian seromucinous tumor 1 trial · 14 incl. sub-types Sub-types →
- Ovarian Brenner tumor 3 trials · 5 incl. sub-types Sub-types →
- Ovarian papillary tumor 0 trials · 2 incl. sub-types Sub-types →
- Ovarian squamous cell neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Ovarian adenoma benign 0 trials Sub-types →
- Ovarian mucinous adenofibroma 0 trials Sub-types →
-
Epithelial tumor of colon 0 trials · 407 incl. sub-types
4 sub-types
- Colon carcinoma 277 trials · 377 incl. sub-types Sub-types →
- Epithelial tumor of the appendix 0 trials · 42 incl. sub-types Sub-types →
- Colon adenoma 17 trials · 32 incl. sub-types Sub-types →
- Neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor 0 trials · 5 incl. sub-types Sub-types →
-
Epithelial neoplasm of rectum 0 trials · 398 incl. sub-types
3 sub-types
- Rectal carcinoma 54 trials · 392 incl. sub-types Sub-types →
- Rectum adenoma 5 trials · 6 incl. sub-types Sub-types →
- Rectum neuroendocrine neoplasm 3 trials · 6 incl. sub-types Sub-types →
-
Epithelial skin neoplasm 0 trials · 310 incl. sub-types
5 sub-types
- Skin carcinoma 34 trials · 281 incl. sub-types Sub-types →
- Benign epithelial skin neoplasm 0 trials · 29 incl. sub-types Sub-types →
- Keratoacanthoma 1 trial Sub-types →
- Sebaceous adenoma 0 trials
- Sweat gland adenoma 0 trials Sub-types →
-
Adenoma 27 trials · 249 incl. sub-types
31 sub-types
- Digestive system adenoma 0 trials · 127 incl. sub-types Sub-types →
- Pituitary gland adenoma 34 trials · 67 incl. sub-types Sub-types →
- Adrenal cortex adenoma 12 trials · 19 incl. sub-types Sub-types →
- Cystadenoma 0 trials · 11 incl. sub-types Sub-types →
- Follicular thyroid adenoma 1 trial · 7 incl. sub-types Sub-types →
- Parathyroid gland adenoma 6 trials Sub-types →
- Oncocytic adenoma 0 trials · 4 incl. sub-types Sub-types →
- Hepatocellular adenoma 2 trials Sub-types →
- Papillary adenoma 2 trials Sub-types →
- Tubular adenoma 2 trials Sub-types →
- Villous adenoma 0 trials · 2 incl. sub-types Sub-types →
- Adenoma of pancreas 1 trial
- Renal adenoma 0 trials · 1 incl. sub-types Sub-types →
- Tubulovillous adenoma 0 trials · 1 incl. sub-types Sub-types →
- Bartholin gland adenoma 0 trials
- Breast adenoma 0 trials Sub-types →
- Clear cell adenoma 0 trials Sub-types →
- Lipoadenoma 0 trials
- Lung adenoma 0 trials Sub-types →
- Microcystic adenoma 0 trials
- Middle ear adenoma 0 trials
- Minor vestibular glands adenoma 0 trials
- Mixed cell adenoma 0 trials Sub-types →
- Mixed somatotroph-lactotroph pituitary gland adenoma 0 trials
- Ovarian adenoma benign 0 trials Sub-types →
- Prostatic adenoma 0 trials
- Rete testis adenoma 0 trials
- Sebaceous adenoma 0 trials
- Sweat gland adenoma 0 trials Sub-types →
- Vaginal adenoma 0 trials Sub-types →
- Water-clear cell adenoma 0 trials
-
Papillary epithelial neoplasm 0 trials · 131 incl. sub-types
9 sub-types
- Papillary carcinoma 8 trials · 112 incl. sub-types Sub-types →
- Papillary urothelial neoplasm 0 trials · 13 incl. sub-types Sub-types →
- Papillomatosis 0 trials · 9 incl. sub-types Sub-types →
- Papilloma 2 trials · 8 incl. sub-types Sub-types →
- Ovarian papillary tumor 0 trials · 2 incl. sub-types Sub-types →
- Papillary adenoma 2 trials Sub-types →
- Endolymphatic sac tumor 1 trial
- Gallbladder papillary neoplasm 0 trials Sub-types →
- Papillary cystic neoplasm 0 trials Sub-types →
-
Basal cell neoplasm 7 trials · 121 incl. sub-types
2 sub-types
- Basal cell carcinoma 111 trials · 120 incl. sub-types Sub-types →
- Benign basal cell neoplasm 0 trials
-
Benign epithelial neoplasm 0 trials · 106 incl. sub-types
25 sub-types
- Benign epithelial skin neoplasm 0 trials · 29 incl. sub-types Sub-types →
- Craniopharyngioma 29 trials Sub-types →
- Adrenal cortex adenoma 12 trials · 19 incl. sub-types Sub-types →
- Papilloma 2 trials · 8 incl. sub-types Sub-types →
- Follicular thyroid adenoma 1 trial · 7 incl. sub-types Sub-types →
- Parathyroid gland adenoma 6 trials Sub-types →
- Kidney oncocytoma 3 trials Sub-types →
- Ameloblastoma 2 trials Sub-types →
- Hepatocellular adenoma 2 trials Sub-types →
- Warthin tumor 1 trial
- Renal adenoma 0 trials · 1 incl. sub-types Sub-types →
- Bartholin gland adenoma 0 trials
- Bartholin gland adenomyoma 0 trials
- Benign adrenal gland pheochromocytoma 0 trials
- Benign basal cell neoplasm 0 trials
- Benign breast adenomyoepithelioma 0 trials
- Benign mesonephroma 0 trials
- Benign ovarian mucinous tumor 0 trials
- Breast adenoma 0 trials Sub-types →
- Lung adenoma 0 trials Sub-types →
- Middle ear adenoma 0 trials
- Minor vestibular glands adenoma 0 trials
- Mucinous adenofibroma 0 trials Sub-types →
- Ovarian adenoma benign 0 trials Sub-types →
- Prostatic adenoma 0 trials
-
Endometrioid tumor 1 trial · 89 incl. sub-types
1 sub-type
- Ovarian endometrial cancer 4 trials · 88 incl. sub-types Sub-types →
-
Intraepithelial neoplasia 25 trials · 71 incl. sub-types
3 sub-types
- Squamous cell intraepithelial neoplasia 26 trials · 43 incl. sub-types Sub-types →
- Prostate intraepithelial neoplasia 2 trials Sub-types →
- Small intestinal intraepithelial neoplasia 1 trial
-
Thymic epithelial neoplasm 14 trials · 56 incl. sub-types
2 sub-types
- Thymic carcinoma 41 trials · 44 incl. sub-types Sub-types →
- Thymoma 44 trials Sub-types →
-
Epithelial tumor of anal canal 0 trials · 34 incl. sub-types
1 sub-type
- Anal canal carcinoma 4 trials · 34 incl. sub-types Sub-types →
-
Sympathetic paraganglioma 0 trials · 16 incl. sub-types
2 sub-types
- Adrenal gland pheochromocytoma 5 trials · 16 incl. sub-types Sub-types →
- Extra-adrenal sympathetic paraganglioma 0 trials
-
Growth hormone-producing pituitary gland neoplasm 0 trials · 5 incl. sub-types
3 sub-types
-
Myoepithelial tumor 2 trials · 4 incl. sub-types
4 sub-types
- Malignant myoepithelioma 2 trials Sub-types →
- Carcinoma ex pleomorphic adenoma 1 trial Sub-types →
- Breast myoepithelial tumor 0 trials Sub-types →
- Parachordoma 0 trials Sub-types →
-
Cystic, mucinous, and serous neoplasm 1 trial · 3 incl. sub-types
1 sub-type
- Mucoepidermoid carcinoma 2 trials Sub-types →
-
Mesonephric neoplasm 1 trial · 3 incl. sub-types
2 sub-types
- Wolffian duct adenocarcinoma 2 trials
- Benign mesonephroma 0 trials
-
Wolffian adnexal tumor 0 trials
-
2 sub-types
- Pancreatic non-functioning delta cell tumor 0 trials
- Pancreatic somatostatinoma 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 2104 trials in this tab.
-
One small incision vs several: robotic stomach cancer surgery put to the test
Cure Not yet recruitingResearchers are comparing two ways of performing robotic surgery to remove stomach cancer: a single-port approach and a standard multi-port approach. The trial enrolls 212 adults with stomach cancer that can be removed with distal gastrectomy. The main question is whether the sin…
Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Cure
Last updated Sep 20, 2026 00:00 UTC
-
Can immunotherapy before surgery stop early oral cancer from returning?
Cure Not yet recruitingThis phase 3 trial tests whether adding sintilimab, an immunotherapy drug, to chemotherapy before surgery helps people with early-stage oral squamous cell carcinoma. Participants are adults aged 18 to 75 with cT2N0M0 oral cancer that can be removed by surgery. Half receive sintil…
Phase 3 • Sponsor: caohaotian • Aim: Cure
Last updated Sep 20, 2026 00:00 UTC
-
Aortic graft used to rebuild windpipe in thyroid cancer surgery
Cure Not yet recruitingResearchers test a new surgical approach for thyroid cancer that has invaded the windpipe. They replace the affected section with a preserved aortic graft supported by a silicone stent. The goal is to remove all cancer and improve survival. The trial includes patients whose cance…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
Can your own immune cells fight advanced cancer?
Cure Not yet recruitingThis trial is testing an experimental therapy called IOV-5001, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack cancer. The study involves adults with advanced solid tumors, including non-small cell lung cancer, triple-negative breast cancer, col…
Phase 1/2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Cure
Last updated Sep 17, 2026 00:00 UTC
-
Can engineered immune cells take down treatment-resistant prostate cancer?
Cure Not yet recruitingThis trial tests ADI-212, a type of cell therapy made from donor immune cells engineered to recognize and attack prostate cancer cells that carry a protein called PSMA. The study enrolls adults with metastatic castration-resistant prostate cancer, a form of the disease that has s…
Phase 1/2 • Sponsor: Adicet Therapeutics • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Can two immunotherapy drugs help rectal cancer patients skip pelvic radiation?
Cure Not yet recruitingResearchers are testing whether a combination of chemotherapy (mFOLFOX6) plus two immunotherapy drugs, suvemcitug and enlonstobart, can shrink high-risk mid-rectal cancer enough to safely skip pelvic radiation before surgery. The trial enrolls 52 adults with locally advanced rect…
Phase 2 • Sponsor: Fudan University • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
Can a Three-Dose immunotherapy cure early lung cancer without surgery?
Cure Not yet recruitingThis phase 2 trial tests whether three cycles of the immunotherapy drug cemiplimab can cure patients with stage I non-small cell lung cancer who cannot undergo surgery or radiation. Researchers will select patients likely to respond to immunotherapy and treat them with cemiplimab…
Phase 2 • Sponsor: The Netherlands Cancer Institute • Aim: Cure
Last updated Sep 10, 2026 00:00 UTC
-
Can a Triple-Drug combo before surgery eliminate EGFR-Mutant lung cancer?
Cure Not yet recruitingThis phase II trial tests whether giving a combination of firmonertinib, anlotinib, and chemotherapy before surgery can shrink or eliminate tumors in people with resectable EGFR-mutant non-small cell lung cancer. The study enrolls adults with stage IIA-IIIB disease who have speci…
Phase 2 • Sponsor: Hubei Cancer Hospital • Aim: Cure
Last updated Sep 10, 2026 00:00 UTC
-
Can engineered immune cells take down advanced prostate cancer?
Cure Not yet recruitingThis trial tests a new type of cell therapy for men with metastatic castration-resistant prostate cancer, a form of the disease that has spread and no longer responds to standard hormone therapy. The treatment uses the patient's own immune cells, called T cells, which are modifie…
Phase 1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Cure
Last updated Sep 06, 2026 00:00 UTC
-
Can a precise Lung-Sparing surgery beat standard lobectomy for early lung cancer?
Cure Not yet recruitingThis trial is testing a surgical technique called septum-guided segmentectomy for people with early-stage (2-3 cm) non-small cell lung cancer. The surgery aims to remove only the diseased part of the lung, guided by natural anatomical landmarks, while preserving healthy tissue. T…
Sponsor: Shanghai Chest Hospital • Aim: Cure
Last updated Aug 23, 2026 00:00 UTC
-
Can your own immune cells beat advanced cancer?
Cure Not yet recruitingThis trial tests a personalized therapy called GT201, made from a patient's own tumor-infiltrating lymphocytes (TILs). The goal is to see if these immune cells, grown in the lab and infused back into the patient, can shrink or eliminate advanced solid tumors. The study includes a…
Phase 1/2 • Sponsor: Gritbio Medicine, Inc. • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
Could a blast of argon plasma wipe out cervical precancer without surgery?
Cure Not yet recruitingThis trial tests whether a single, outpatient treatment using low-thermal argon plasma can clear grade 2 cervical intraepithelial neoplasia (CIN2), a precancerous condition. Participants receive either the plasma treatment, a sham procedure, or standard active surveillance. The m…
Sponsor: University Hospital Tuebingen • Aim: Cure
Last updated Aug 05, 2026 00:00 UTC
-
Could a single drug replace surgery for rectal cancer?
Cure Not yet recruitingThis study tests whether giving the immunotherapy drug dostarlimab for a longer period can completely eliminate tumors in people with a specific genetic type of rectal cancer. Participants have stage II or III rectal cancer that is mismatch repair deficient (dMMR) or microsatelli…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Cure
Last updated Aug 05, 2026 00:00 UTC
-
Can a Patient's own immune cells be supercharged to fight ovarian cancer?
Cure Not yet recruitingThis trial is testing whether a personalized cell therapy can help women with ovarian cancer that has returned. Doctors will remove a tumor, extract immune cells called tumor-infiltrating lymphocytes (TILs), and boost them in the lab before infusing them back into the patient. Af…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
Sparing the liver: targeted chemoembolization meets lenvatinib in liver cancer
Disease control Not yet recruitingResearchers are testing whether a liver-sparing form of chemoembolization, called partial TACE, can boost the anti-tumor effects of the drug lenvatinib in people with liver cancer that cannot be removed by surgery. The trial enrolls about 40 adults with hepatocellular carcinoma w…
Phase 2 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Triple attack on pancreatic tumors: can radiation and immunotherapy make inoperable cancer operable?
Disease control Not yet recruitingResearchers test whether a short course of targeted radiation followed by the immunotherapy drug adebrelimab and NALIRIFOX chemotherapy can shrink locally advanced pancreatic cancer enough to allow surgery. The trial enrolls 36 adults with previously untreated pancreatic ductal a…
Phase 2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Radioactive missile aims at stubborn kidney tumors
Disease control Not yet recruitingResearchers are testing a radiopharmaceutical called 161Tb-PSMA-1 in adults with metastatic clear cell renal cell carcinoma that has worsened after at least two prior treatments, including immunotherapy and drugs that block blood vessel growth. The trial has two parts: a dose-esc…
Phase 1 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Two-Drug combo targets stubborn KRAS lung cancer
Disease control Not yet recruitingResearchers are testing whether combining BL-B01D1, an experimental antibody-drug conjugate, with glecirasib, a targeted KRAS G12C inhibitor, can shrink tumors in adults with locally advanced or metastatic non-small cell lung cancer that carries a KRAS G12C mutation. The phase 2 …
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Radioactive drug targets Hard-to-Treat thyroid cancer
Disease control Not yet recruitingThis study tests a radioactive drug called 177Lu-DOTA-EB-TATE in 18 adults with a rare thyroid cancer (Hurthle cell) that has spread and not responded to standard radioactive iodine treatment. The drug is designed to seek out and attach to cancer cells. Participants will receive …
Phase 1/2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat adrenal tumors?
Disease control Not yet recruitingThis phase 2 trial is testing whether the drug ivonescimab can help control advanced or metastatic adrenal cancers, specifically adrenocortical carcinoma (ACC) and pheochromocytoma/paraganglioma (PPGL), that have not responded to prior treatment. About 20 adults with these rare c…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a vaccine plus a Blood-Vessel blocker stop airway growths from coming back?
Disease control Not yet recruitingThis phase II trial tests whether combining bevacizumab, a drug that limits blood vessel growth, with PRGN-2012, a vaccine-based therapy, can help adults with recurrent respiratory papillomatosis (RRP) avoid needing more surgeries. RRP causes wart-like growths in the airway that …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn solid tumors
Disease control Not yet recruitingThis trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Lab-Grown tumor organoids could pick the right bladder chemo
Disease control Not yet recruitingResearchers are testing whether drug testing in patient-derived organoids can guide chemotherapy for low-grade non-muscle invasive bladder cancer. Adults with primary or recurrent low-grade bladder cancer receive one of four chemo drugs, epirubicin, mitomycin C, gemcitabine, or d…
Phase 2 • Sponsor: Hospital Centre Biel/Bienne • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill-chemo combo takes on hard-to-treat cancers
Disease control Not yet recruitingThis study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a simple checklist help surgeons remove every last cancer cell?
Disease control Not yet recruitingResearchers are testing whether a shared checklist used during lung cancer surgery helps surgeons achieve cleaner, more complete tumor removal. The trial enrolls adults with early-stage non-small cell lung cancer who are scheduled for surgery. Half the participating hospitals use…
Sponsor: Fondation Hôpital Saint-Joseph • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Liver tumors targeted directly: old pump, new drug
Disease control Not yet recruitingThis trial tests whether a drug called carfilzomib, given directly to the liver through an implanted pump, is safe for people whose colon, adrenal, or bile duct cancer has spread to the liver and persists after prior pump therapy. Participants receive weekly infusions of the drug…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New chemo cocktail targets pancreatic cancer at every stage
Disease control Not yet recruitingResearchers are testing a chemotherapy combination built around albumin-bound paclitaxel (II) for people with pancreatic cancer. The study has three groups: one for advanced cancer that cannot be removed by surgery, one for cancer that may be removable and receives treatment befo…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Engineered immune cells take aim at deadly lung cancer
Disease control Not yet recruitingThis early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein c…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Dual immunotherapy plus chemo before surgery: a new way to shrink stomach tumors?
Disease control Not yet recruitingResearchers are testing whether combining an experimental dual immunotherapy drug called QL1706 with standard chemotherapy (docetaxel, oxaliplatin and S-1) before surgery can help patients with locally advanced gastric or gastroesophageal junction cancer. The study enrolls 34 adu…
Phase 2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
Disease control Not yet recruitingResearchers are testing a new biological therapy called BI 4060107 in adults with advanced solid tumors that cannot be removed by surgery. The trial is for people who have tried all available treatments and have no other options. The main goal is to find the highest dose that peo…
Phase 1 • Sponsor: AIMEDBIO • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New vaccine combo aims to halt prostate cancer growth without surgery
Disease control Not yet recruitingThis phase 2 trial tests a combination of a vaccine (TriAdeno) and an immune-boosting drug (N-803) in 52 men with early-stage, low- or medium-risk prostate cancer who are currently on active surveillance. The vaccine targets three proteins found in prostate cancer cells, while N-…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Bacteria-Based immunotherapy targets pancreatic tumors in first human test
Disease control Not yet recruitingResearchers are testing a new immunotherapy called Lm-LLO-TT in adults with advanced pancreatic ductal adenocarcinoma that has already been treated with chemotherapy. Lm-LLO-TT uses a weakened form of Listeria bacteria engineered to carry a tetanus toxoid antigen, aiming to spark…
Phase 1 • Sponsor: Loki Therapeutics, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Old antiparasitic drug joins chemo in pancreatic cancer fight
Disease control Not yet recruitingResearchers at the University of Oklahoma are testing whether adding pentamidine, an antiparasitic drug, to standard modified FOLFIRINOX chemotherapy is safe and helps shrink tumors in people with advanced or metastatic pancreatic cancer. Up to 30 adults with confirmed locally ad…
Phase 1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Zapping resistant tumors: could radiation extend the life of current breast cancer therapy?
Disease control Not yet recruitingThis trial is for people with ER-positive, HER2-negative advanced breast cancer whose disease has started to grow in a few spots while on hormone therapy and a CDK4/6 inhibitor. It tests whether adding targeted radiation (SABR) to those spots allows patients to stay on their curr…
Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Daily pill giredestrant put to the test for sticking with breast cancer treatment
Disease control Not yet recruitingResearchers are studying giredestrant, an experimental daily pill, in people with estrogen receptor-positive, HER2-negative early breast cancer. The trial enrolls about 1,500 participants, including some who switch to giredestrant after other treatments. It tracks how many people…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can zapping liver and lung tumors boost treatment for nasopharyngeal cancer?
Disease control Not yet recruitingResearchers are testing whether adding CT-guided thermal ablation of liver or lung metastases to standard systemic therapy improves tumor response in people with nasopharyngeal carcinoma. The trial enrolls 138 adults whose primary tumor was cured but who later developed up to fiv…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Gene therapy joins forces with chemo and immunotherapy to fight bladder cancer
Disease control Not yet recruitingThis phase 2 trial tests whether adding a gene therapy called nadofaragene firadenovec to standard chemotherapy and immunotherapy can improve outcomes for people with muscle invasive bladder cancer before they have their bladder removed. The gene therapy is placed directly into t…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a new antibody boost treatment for Hard-to-Treat HER2 breast cancer?
Disease control Not yet recruitingResearchers are testing whether adding an experimental drug called HLX22 to standard trastuzumab and chemotherapy helps people with locally advanced or metastatic HER2-positive breast cancer that has already been treated with a HER2 ADC. About 90 adults will receive either HLX22 …
Phase 2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
First-in-Human biologic JUR-003 put to the test against metastatic prostate cancer
Disease control Not yet recruitingResearchers are running a first-in-human Phase 1 trial of JUR-003, an intravenous biologic, in adults with metastatic prostate cancer. The study has two parts: a dose-escalation phase to find the highest dose people can tolerate, and a dose-expansion phase to look at early anti-t…
Phase 1 • Sponsor: Juri Biosciences, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Two oral drugs join chemotherapy in a bid to shrink pancreatic tumors
Disease control Not yet recruitingResearchers are testing whether adding two oral drugs, avutometinib and defactinib, to standard chemotherapy (mFOLFIRINOX) is safe and can slow or shrink pancreatic ductal adenocarcinoma. The trial has two parts: one for people whose cancer has spread, and one for people whose ca…
Phase 1/2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New injectable drug tested against Hard-to-Treat solid tumors
Disease control Not yet recruitingResearchers are running a Phase I trial of HEC-921, an experimental drug given by intravenous infusion, in adults with advanced malignant solid tumors. The study first gives HEC-921 alone to find the highest dose people can tolerate, then tests it in combination with oxaliplatin,…
Phase 1 • Sponsor: Sunshine Lake Pharma Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can older women with breast cancer skip chemo? new trial tests CDK4/6 inhibitors
Disease control Not yet recruitingResearchers are testing whether women aged 65 and older with early-stage, lymph node-positive, ER+/HER2- breast cancer can safely skip chemotherapy. Participants receive CDK4/6 inhibitors, with or without endocrine therapy, after surgery. The trial tracks how many women remain fr…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a smaller dose of this cancer drug still work? new trial aims to find out
Disease control Not yet recruitingThis phase 2 trial is testing whether a lower dose of the immunotherapy drug nivolumab, given less often, can still control cancer in people with various advanced or metastatic cancers. The goal is to see if a cheaper, more accessible regimen works as well as the standard high-co…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental drug put to the test against Hard-to-Treat GI cancers
Disease control Not yet recruitingResearchers are testing an experimental injectable drug called ALK-N001 in adults with advanced gastrointestinal tumors, including esophageal and colorectal cancers that have worsened after standard treatment. The phase II trial gives the drug intravenously every two weeks at one…
Phase 2 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Two-Drug combo takes aim at Hard-to-Treat lung cancer
Disease control Not yet recruitingResearchers are testing whether adding the immunotherapy adebrelimab to HS-20093 (risvutatug rezetecan) works better than HS-20093 alone in adults with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated and has no actionable gene changes.…
Phase 2 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Protein-Guided missiles: can mass spectrometry match the right drug to the right tumor?
Disease control Not yet recruitingResearchers are testing whether measuring specific proteins in tumors can help match patients with advanced pancreatic or breast cancer to antibody-drug conjugates that are more likely to work for them. The trial enrolls 225 adults whose cancer has progressed after prior treatmen…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can scans predict which liver cancer patients need extra local therapy?
Disease control Not yet recruitingResearchers are studying whether adding local treatments such as ablation, radiotherapy, or transarterial therapy to the drug combination atezolizumab plus bevacizumab helps certain patients with unresectable hepatocellular carcinoma live longer. The study uses medical records an…
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New antibody pair takes aim at advanced liver cancer in major trial
Disease control Not yet recruitingResearchers are testing whether a new combination of two antibodies, JS207 and JS007, works better than the standard first-line treatment of toripalimab plus bevacizumab for advanced liver cancer. The trial enrolls about 560 adults with liver cancer that cannot be removed by surg…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a new drug combo shrink High-Risk throat tumors?
Disease control Not yet recruitingThis phase II trial tests whether the experimental drug BL-B01D1, given with or without a PD-1 antibody, can improve tumor shrinkage in people with high-risk locally advanced nasopharyngeal carcinoma, a type of throat cancer. Participants also receive standard chemotherapy drugs …
Phase 2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a drug combo shrink esophageal tumors before surgery?
Disease control Not yet recruitingResearchers are testing whether giving sacituzumab tirumotecan plus toripalimab before surgery helps people with locally advanced esophageal squamous cell carcinoma. Participants receive three cycles of the combination, then undergo standard surgery to remove the tumor. The main …
Phase 2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a breast cancer combo be safer for diabetics?
Disease control Not yet recruitingThis trial is testing whether a combination of drugs—inavolisib plus fulvestrant, with or without palbociclib—is safe for people with a specific type of advanced breast cancer (HR+, HER2-negative) that has a PIK3CA mutation, and who also have type 2 diabetes. The main focus is on…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can two drugs spare the bladder in aggressive bladder cancer?
Disease control Not yet recruitingResearchers are testing whether combining enfortumab vedotin and pembrolizumab can shrink muscle-invasive bladder cancer enough to avoid removing the bladder or using radiation. The trial enrolls 25 adults with confirmed muscle-invasive urothelial carcinoma that has not spread. P…
Phase 2 • Sponsor: University of Utah • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo takes aim at a Hard-to-Treat lung cancer mutation
Disease control Not yet recruitingResearchers are testing whether adding the experimental oral drug HS-10370 to platinum-based chemotherapy, with or without the immunotherapy adebrelimab, works better than tislelizumab plus chemotherapy. The trial enrolls about 448 adults with previously untreated, locally advanc…
Phase 3 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers
Disease control Not yet recruitingResearchers are running a first-in-human study of MGC030, an antibody-drug conjugate, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The trial includes participants with urothelial, colorectal, gastric, gastroesophageal, esop…
Phase 1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for Hard-to-Treat prostate cancer: experimental drug zanzalitinib under study
Disease control Not yet recruitingThis study tests a new drug called zanzalitinib in people with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to soft tissues or organs. The goal is to see if the drug can slow or stop cancer growth. About 19 participants will receive…
Phase 2 • Sponsor: Pedro Barata, MD, MSc • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can zapping residual lung cancer spots extend remission?
Disease control Not yet recruitingResearchers are testing whether adding focused radiation to the few remaining cancer spots helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their disease getting worse. Participants first receive a third-generation EGFR-targeted drug plus plat…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Antibody-Drug conjugate takes aim at c-Met-High lung cancer
Disease control Not yet recruitingResearchers are testing whether an experimental drug called telisotuzumab adizutecan works better than standard chemotherapy for people with non-squamous non-small cell lung cancer that has grown after earlier treatment. The trial enrolls about 660 participants whose tumors are E…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a targeted drug delivery system shrink lung tumors?
Disease control Not yet recruitingThis trial tests an experimental drug called TUB-040 in adults with advanced non-small cell lung cancer that cannot be removed with surgery or has spread. TUB-040 is designed to attach to a protein on cancer cells and deliver a toxic payload directly to the tumor, potentially kil…
Phase 2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a targeted pill be safely used for RET-Driven cancers in india?
Disease control Not yet recruitingResearchers are studying the safety of selpercatinib, an oral drug, in people in India with advanced cancers that have changes in the RET gene. The trial includes adults with RET fusion-positive non-small cell lung cancer and adults and children aged 12 and older with RET-mutant …
Phase 4 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Two-Drug combo targets Hard-to-Treat recurrent small cell lung cancer
Disease control Not yet recruitingResearchers are testing a combination of paclitaxel polymeric micelles and ivonescimab in adults with small cell lung cancer that has returned or stopped responding after platinum-based chemotherapy and anti-PD-1/PD-L1 therapy. The phase 2 trial aims to see how many participants'…
Phase 2 • Sponsor: Shaodong Hong • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a Weight-Loss drug and an IUD treat early uterine cancer without surgery?
Disease control Not yet recruitingResearchers are testing whether a combination of semaglutide (Wegovy), a levonorgestrel-releasing intrauterine device (LNG-IUD), and a structured weight loss program can treat endometrial atypical hyperplasia or early-stage, grade 1 endometrioid endometrial cancer in women who wa…
Phase 2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a new drug combo keep advanced nasopharyngeal cancer at bay?
Disease control Not yet recruitingThis phase III trial is testing whether adding an experimental drug called BL-B01D1 to standard maintenance therapy with a PD-1 antibody can help people with recurrent or metastatic nasopharyngeal carcinoma live longer without their cancer progressing. Participants first receive …
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Radiation plus targeted antibody tested in older head and neck cancer patients
Disease control Not yet recruitingResearchers are testing whether adding nimotuzumab to intensity-modulated radiation therapy helps older adults with locally advanced head and neck squamous cell carcinoma who cannot tolerate standard chemotherapy. The study enrolls patients aged 65 and older with EGFR-positive tu…
Phase 2 • Sponsor: Ke Hu • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Two-Drug combo aims to shrink lung tumors before surgery
Disease control Not yet recruitingResearchers are testing whether giving toripalimab plus sacituzumab tirumotecan before surgery helps people with resectable non-small cell lung cancer. The trial enrolls about 30 adults with stage II to IIIB disease that has not been treated and lacks certain driver mutations. Pa…
Phase 2 • Sponsor: Shaodong Hong • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can immunotherapy plus chemo melt colorectal tumors before surgery?
Disease control Not yet recruitingResearchers are testing whether adding serplulimab, an immunotherapy, to standard CAPOX chemotherapy and bevacizumab can shrink locally advanced colorectal tumors before surgery. The study enrolls about 85 adults with locally advanced rectal adenocarcinoma. The main goal is to se…
Phase 2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can shrinking pancreatic tumors before surgery improve outcomes?
Disease control Not yet recruitingResearchers are testing whether giving chemotherapy before surgery helps people with pancreatic cancer that can be removed. The trial compares two drug combinations, gemcitabine plus nab-paclitaxel and FOLFIRINOX, in adults with resectable pancreatic adenocarcinoma. After treatme…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Experimental combo aims to tackle advanced liver cancer
Disease control Not yet recruitingThis study tests an experimental drug called WGI-0301 combined with lenvatinib in 80 people with advanced liver cancer who have already tried one treatment. The goal is to see if the combination is safe, tolerable, and shrinks tumors. It is an open-label, non-placebo trial across…
Phase 1/2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug takes aim at ROS1-Positive lung cancer in Head-to-Head trial
Disease control Not yet recruitingResearchers are comparing an experimental oral drug called JYP0322 with crizotinib in adults who have not yet received treatment for ROS1-positive locally advanced or metastatic non-small cell lung cancer. The phase III trial aims to see which drug keeps cancer from worsening lon…
Phase 3 • Sponsor: Guangzhou JOYO Pharma Co., Ltd • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a new drug help keep bladder cancer at bay?
Disease control Not yet recruitingThis phase 2 trial is testing an experimental drug called RAG-01, either alone or combined with chemotherapy, in people with a type of bladder cancer that hasn't spread into the muscle layer. The study aims to see if the drug can improve how long patients go without their cancer …
Phase 2 • Sponsor: Ractigen Therapeutics. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Two-Drug combo targets HER2-Positive stomach cancer after First-Line failure
Disease control Not yet recruitingResearchers are testing whether combining trastuzumab with retlirafusp alfa helps people with HER2-positive gastric or gastroesophageal junction cancer that has worsened after standard first-line treatment. The trial enrolls about 35 adults whose tumors test HER2 2+ or 3+. Partic…
Phase 2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Immune-Drug combo aims to shrink rare kidney tumors before surgery
Disease control Not yet recruitingResearchers are testing two drugs, toripalimab and axitinib, in adults with advanced non-clear cell kidney cancer or renal medullary carcinoma who have not received prior treatment and still have their primary kidney tumor. Everyone receives the drugs for about 12 weeks. Then a t…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Could a drug combo spare bladder cancer patients from surgery?
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, given before surgery to people with muscle-invasive bladder cancer or upper tract urothelial carcinoma. The goal is to see if the drugs can shrink or eliminate the cancer enough that some b…
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Antibody-Drug conjugate takes aim at relapsed ovarian cancer
Disease control Not yet recruitingResearchers are testing whether torvutatug samrotecan, alone or with bevacizumab, works better than standard care as maintenance therapy for people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer. The trial enrolls about 600 participants who…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can drug cocktail spare rectal cancer patients from surgery?
Disease control Not yet recruitingResearchers test whether giving mFOLFOXIRI plus bevacizumab before surgery can shrink locally advanced rectal cancer enough to avoid removing the rectum. Adults with stage II or III rectal cancer receive six cycles of the drug combination. Depending on how well the tumor responds…
Phase 2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental infusion drug tested against recurrent nasopharyngeal cancer
Disease control Not yet recruitingResearchers are testing an experimental drug called BL-M08D1 in adults with nasopharyngeal carcinoma that has come back or spread, as well as other solid tumors. Participants receive the drug by intravenous infusion every three weeks. The trial aims to find a safe dose for furthe…
Phase 1/2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a new drug boost immunotherapy against Hard-to-Treat stomach cancer?
Disease control Not yet recruitingResearchers are testing whether adding an experimental drug called ONO-4578 to nivolumab and chemotherapy helps people with advanced or metastatic gastric cancer, esophagogastric junction cancer, or esophageal adenocarcinoma. The trial enrolls about 600 adults whose tumors are HE…
Phase 3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a targeted drug shrink advanced penile cancer when chemotherapy stops working?
Disease control Not yet recruitingThis Phase 2 trial tests amivantamab, a targeted drug given as a shot under the skin, in adults with advanced penile cancer that has spread or returned after at least one round of platinum-based chemotherapy. The study includes two groups based on HPV status and measures how many…
Phase 2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Radiation and immunotherapy combo tested against advanced lung cancer
Disease control Not yet recruitingResearchers are testing whether adding stereotactic radiation to two drugs, envafolimab and endostar, helps people with stage IV non-small cell lung cancer. Participants have tumors without common EGFR, ALK, or ROS1 mutations and have not received prior systemic treatment. Everyo…
Phase 2 • Sponsor: The First People's Hospital of Lianyungang • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Immunotherapy combo aims to turn inoperable liver tumors into operable ones
Disease control Not yet recruitingResearchers test whether adding retlirafusp alfa, an experimental immunotherapy, to standard targeted drugs and chemotherapy can shrink colorectal cancer that has spread to the liver enough to allow surgery. The trial enrolls about 80 adults with initially unresectable liver meta…
Phase 2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
Disease control Not yet recruitingThis trial is testing whether a new drug called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer and delay cancer growth compared to standard chemotherapy. The study includes adults with high-grade serous or…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Triple therapy aims to stall pancreatic cancer
Disease control Not yet recruitingResearchers are testing whether combining retlirafusp alfa, famitinib, and AG chemotherapy (nab-paclitaxel plus gemcitabine) can slow cancer growth in people with unresectable pancreatic cancer. The trial enrolls about 88 adults with locally advanced or metastatic pancreatic duct…
Phase 2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can precision radiation and immunotherapy team up against abdominal colorectal cancer?
Disease control Not yet recruitingResearchers are testing whether adding targeted radiation plus the immunotherapy drug cadonilimab to standard second-line chemotherapy helps adults with colorectal cancer that has spread only to the peritoneum. The trial enrolls about 198 participants and randomly assigns them to…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Saline barrier lets heat target liver tumors near the diaphragm
Disease control Not yet recruitingResearchers are studying whether microwave ablation, helped by a saline injection that separates the liver tumor from the diaphragm, is safe and effective for hepatocellular carcinoma. They compare this approach with surgical resection in patients whose single tumor is 5 cm or sm…
Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a targeted drug keep ovarian cancer at bay longer?
Disease control Not yet recruitingThis trial is testing whether a targeted therapy called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with newly diagnosed advanced ovarian cancer live longer without their cancer growing. Participants have already completed first-line platinum-…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New combo radiation approach aims to control advanced lung cancer
Disease control Not yet recruitingThis study tests whether giving high-precision radiation (SBRT) to the main tumor and nearby lymph nodes, along with standard chemotherapy, can better control stage III non-small cell lung cancer. The trial will enroll 20 adults whose tumors are less than 6 cm and who have not sp…
Sponsor: All India Institute of Medical Sciences • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New vaccine combo takes on tough lung cancer in early trial
Disease control Not yet recruitingThis early-phase study tests a new cancer vaccine (EVM14) combined with an immunotherapy drug (ivonescimab) in 13 people with advanced squamous non-small cell lung cancer that has not been treated before. The main goals are to check safety and find the right dose, while also look…
Phase 1 • Sponsor: Everest Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
A Two-Target antibody takes aim at advanced solid tumors
Disease control Not yet recruitingResearchers are testing an experimental antibody called 3SC009 in adults with advanced or metastatic solid tumors that have not responded to other treatments. The drug is a bispecific antibody, meaning it binds to two different targets on cancer cells, CD47 and EpCAM. The trial h…
Phase 1 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Antibody-Drug conjugate aims to hit Hard-to-Treat penile cancer
Disease control Not yet recruitingPenile squamous cell carcinoma is a rare and aggressive cancer with limited options once it progresses after platinum-based chemotherapy. This phase 2 trial tests sacituzumab tirumotecan, an antibody-drug conjugate that targets the TROP-2 protein on cancer cells, in about 37 part…
Phase 2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a common cholesterol pill help chemotherapy fight ovarian cancer?
Disease control Not yet recruitingResearchers are studying whether adding daily atorvastatin to standard chemotherapy and surgery changes the immune cells inside advanced high grade serous tumors of the ovary, fallopian tube, or peritoneum. The trial enrolls 40 adults with Stage III or IV disease who cannot have …
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Blood test could guide cancer treatment, reducing side effects
Disease control Not yet recruitingThis study tests whether a blood test that detects HPV DNA can help doctors choose the right treatment for people with HPV-positive oropharyngeal cancer. About 116 participants with stage I to III cancer will receive either the immunotherapy drug pembrolizumab (Keytruda) or stand…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a new drug combo keep ovarian cancer from coming back?
Disease control Not yet recruitingThis phase 3 trial tests whether adding an experimental drug called BG-C9074 to bevacizumab helps adults with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease has not worsened after initial platinum-based chemotherapy plus bevacizumab. Participants r…
Phase 3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Coaching may boost cancer pill adherence in new study
Disease control Not yet recruitingThis study looks at whether extra education and counseling helps women with HR+/HER2- early breast cancer take their prescribed medication, abemaciclib, more consistently. About 257 women will either receive standard care or additional coaching. The main goal is to see if coachin…
Sponsor: Institut fuer Frauengesundheit • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can electric pulses destroy lung tumors without surgery?
Disease control Not yet recruitingThis trial tests a device that uses pulsed electric fields to destroy lung tumors. It is for people with early-stage non-small cell lung cancer or lung metastases that cannot be removed with surgery or treated with radiotherapy. Participants receive the ablation under general ane…
Sponsor: Energenx Medical LTD. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a migraine drug make oral cancer treatment hit harder?
Disease control Not yet recruitingResearchers are testing whether adding rimegepant to standard chemoimmunotherapy before surgery helps shrink oral or oropharyngeal squamous cell carcinoma more effectively. The trial enrolls adults with primary or recurrent disease who are scheduled for surgery. Participants rece…
Phase 2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Weight-Loss drug meets hormonal IUD in hunt for Surgery-Free cancer care
Disease control Not yet recruitingResearchers are testing whether adding tirzepatide, a weekly drug that treats obesity and diabetes, to a standard levonorgestrel-releasing intrauterine device can help clear early endometrial cancer or a precancerous condition called endometrial intraepithelial neoplasia. The stu…
Early phase 1 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a guided missile for chemo hit tumors harder and spare healthy tissue?
Disease control Not yet recruitingResearchers are testing a new drug called TS-104 in adults with advanced solid tumors, including lung, head and neck, ovarian, endometrial, esophageal, and gastric cancers. TS-104 is a peptide drug conjugate: it uses a targeting peptide to carry the chemotherapy drug MMAE directl…
Phase 1 • Sponsor: TwoStep Therapeutics, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Precision radiation may boost hormone therapy for advanced prostate cancer
Disease control Not yet recruitingThis study tests whether adding precisely targeted radiation to standard hormone therapy helps men with metastatic hormone-sensitive prostate cancer. All participants first receive six months of darolutamide plus androgen deprivation therapy. Those whose cancer has not progressed…
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a stronger radiation dose fix hormone overload?
Disease control Not yet recruitingResearchers are testing whether a higher dose of proton beam therapy can normalise hormone levels better than standard radiotherapy in people with functioning pituitary tumours, including acromegaly and Cushing's disease. Participants receive about six weeks of either standard-do…
Phase 3 • Sponsor: University College, London • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a new drug combo hold up in Real-World prostate cancer care?
Disease control Not yet recruitingThis study follows men in India with metastatic hormone-sensitive prostate cancer who are already receiving darolutamide plus androgen deprivation therapy as part of their routine care. Researchers will track side effects, treatment changes, and lab results over up to one year. T…
Sponsor: Bayer • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can an oral drug that starves tumors help Hard-to-Treat cancers?
Disease control Not yet recruitingResearchers are testing an investigational oral drug called catequentinib hydrochloride (AL3818) in adults with advanced or metastatic endometrial cancer, low grade serous ovarian cancer, soft tissue sarcoma, or glioblastoma. The trial has two parts: a phase 1b part to find safe …
Phase 1/2 • Sponsor: Advenchen Pharmaceuticals, LLC. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New immunotherapy combo put to the test in advanced liver cancer
Disease control Not yet recruitingResearchers are testing whether an experimental immunotherapy called ZG005, combined with bevacizumab, works better than the standard combination of sintilimab and bevacizumab for people with advanced hepatocellular carcinoma who have not yet received systemic treatment. The tria…
Phase 3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a fir…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Targeted drug 3D185 put to the test against FGFR2-Altered bile duct cancer
Disease control Not yet recruitingResearchers are testing a drug called 3D185 in people with advanced or metastatic cholangiocarcinoma, a type of bile duct cancer, whose tumors have changes in the FGFR2 gene. All participants have already received at least one other systemic cancer treatment that stopped working.…
Phase 2 • Sponsor: 3D Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can pairing immunotherapy drugs shrink Hard-to-Treat skin cancers?
Disease control Not yet recruitingResearchers are testing the drug cemiplimab, given alone or with other anti-cancer drugs, in people with locally advanced basal cell carcinoma that cannot be treated with surgery or radiation. The trial compares how well the combinations work against cemiplimab by itself and trac…
Phase 2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a new drug extend remission in advanced ovarian cancer?
Disease control Not yet recruitingThis trial tests whether adding an experimental drug called INCB123667 to the standard maintenance therapy bevacizumab can delay cancer recurrence in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. Participants must have completed initial chemotherapy …
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a targeted drug conjugate outsmart advanced colorectal cancer?
Disease control Not yet recruitingThis phase 1 trial tests an investigational drug called DEM301 in adults with advanced colorectal cancer that has progressed after standard treatments. DEM301 is an antibody-drug conjugate, a type of therapy designed to deliver a toxic agent directly to cancer cells. The study ai…
Phase 1 • Sponsor: DEM BioPharma, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo aims to shrink liver tumors in kidney cancer patients
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs, envafolimab and lenvatinib, as a first treatment for people with clear cell kidney cancer that has spread to the liver. The study will enroll 30 participants and measure how well the drugs shrink liver tumors. It is not yet rec…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
A helping hand: can navigators keep breast cancer treatment on track?
Disease control Not yet recruitingThis study tests whether a patient navigator program can help breast cancer patients with social challenges—like food, housing, or transportation issues—stay on schedule with their treatment. Participants will be contacted by a navigator every three weeks to connect them with com…
Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can an immunotherapy plus chemotherapy keep High-Risk bladder cancer at bay?
Disease control Not yet recruitingThis phase 2 trial tests whether combining the immunotherapy drug toripalimab with the chemotherapy drug gemcitabine, given directly into the bladder, can reduce the chance of high-risk non-muscle-invasive bladder cancer returning after surgery. Adults aged 18 to 85 who have had …
Phase 2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new drug combo outsmart resistant breast cancer?
Disease control Not yet recruitingThis phase 1 trial is testing whether combining the experimental drug zotatifin with the chemotherapy carboplatin can help people with advanced triple-negative breast cancer (TNBC) that has not responded to standard treatments. The study aims to find the safest and most effective…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a 16-Hour fast supercharge immunotherapy against rectal cancer?
Disease control Not yet recruitingThis phase II trial is testing whether a 16-hour fast before each dose of the immunotherapy drug serplulimab, combined with chemotherapy, can improve outcomes for people with a common type of locally advanced rectal cancer. The approach aims to boost the immune system's ability t…
Phase 2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can an oral drug R01 fight advanced lung, stomach, and esophageal cancers?
Disease control Not yet recruitingThis early-phase trial tests an oral drug called R01 in people with advanced squamous cell lung cancer, gastric cancer, or esophageal cancer that has progressed after standard treatment. The study aims to find the safest dose and check whether R01 can shrink tumors. Participants …
Phase 1 • Sponsor: Beijing Anjianxi Bio-Medical Technology Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for tough bladder cancer: immune drug plus chemo combo enters trial
Disease control Not yet recruitingThis study tests whether adding chemotherapy drugs (gemcitabine and mitomycin C) directly into the bladder alongside an immune-boosting drug (toripalimab) works better than toripalimab alone for people with a high-risk bladder cancer that did not respond to standard BCG therapy. …
Phase 2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new drug shrink tumors that resist standard care?
Disease control Not yet recruitingThis early-stage trial tests an experimental drug called STRO-006 in adults with advanced solid tumors, including head and neck, lung, esophageal, gastric, colorectal, endometrial, bladder, and breast cancers that have not responded to standard treatments. The study has three par…
Phase 1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a Two-Drug immunotherapy combo shrink MSS colon cancer before surgery?
Disease control Not yet recruitingThis phase 2 trial tests whether giving two immunotherapy drugs, pembrolizumab and porustobart, before surgery can shrink tumors in adults with a common type of colon cancer called MSS (microsatellite stable) that has not spread. Participants receive the drugs through a vein, wit…
Phase 2 • Sponsor: Solstice Oncology, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a Triple-Drug induction boost anal cancer remission?
Disease control Not yet recruitingThis phase 2 trial tests whether adding the investigational drug becotatug vedotin to pucotenlimab and capecitabine before standard chemoradiotherapy can improve outcomes for people with locally advanced squamous cell carcinoma of the anal canal. Participants first receive two cy…
Phase 2 • Sponsor: Wang Xin • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new drug shrink advanced solid tumors?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new drug outperform standard chemo for advanced breast cancer?
Disease control Not yet recruitingThis trial compares an experimental drug called HB1801 with the standard chemotherapy docetaxel (Taxotere) in people with HER2-negative advanced breast cancer. The goal is to see whether HB1801 can delay cancer growth better than docetaxel. Participants receive either HB1801 or d…
Phase 3 • Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New personalized vaccine trial aims to boost immune attack on aggressive breast cancer
Disease control Not yet recruitingThis early-phase trial is testing whether a personalized cancer vaccine, made from a patient's own tumor, can safely boost the immune system's ability to fight triple negative breast cancer. About 30 newly diagnosed patients will receive the vaccine along with standard chemothera…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New chemo combo shows promise for tough lung cancer
Disease control Not yet recruitingThis Phase 2 trial tests whether adding lurbinectedin to paclitaxel works better than paclitaxel alone for people with advanced small cell lung cancer that has returned after first treatment. About 69 adults will be randomly assigned to one of two groups. The study measures how m…
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a bladder rinse before surgery keep bladder cancer at bay?
Disease control Not yet recruitingThis phase III trial tests whether giving the drug Alpha1H directly into the bladder before standard surgery lowers the risk of cancer returning in adults with low- to intermediate-risk non-muscle-invasive bladder cancer. Participants are randomly assigned to receive either six A…
Phase 3 • Sponsor: Hamlet Pharma AB • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for Hard-to-Treat anal and rectal cancers
Disease control Not yet recruitingThis study tests a drug called sacituzumab tirumotecan in 20 people with advanced anal or rectal cancer that has spread or cannot be removed and has not responded to other treatments. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive t…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a smart drug shrink rare gynecologic tumors?
Disease control Not yet recruitingThis phase II trial tests whether sacituzumab tirumotecan (Sac-TMT) can shrink tumors in people with advanced or metastatic squamous cell carcinoma of the vagina or vulva. These cancers are rare, and there is no standard second-line treatment. Sac-TMT is an antibody-drug conjugat…
Phase 2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a smart drug outsmart pancreatic cancer?
Disease control Not yet recruitingThis phase III trial tests an experimental drug called YL201 against standard chemotherapy in people with metastatic pancreatic cancer that has progressed after gemcitabine-based treatment. YL201 is designed to deliver a toxin directly to cancer cells that carry a specific marker…
Phase 3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a Cancer-Targeting drug slow advanced prostate cancer?
Disease control Not yet recruitingThis phase 3 trial tests whether risvutatug rezetecan, an antibody-drug conjugate that delivers a toxin directly to prostate cancer cells, can slow or shrink tumors better than standard hormone therapy. About 684 men with metastatic castration-resistant prostate cancer will recei…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo aims to slow advanced cervical cancer
Disease control Not yet recruitingThis study tests whether adding a glutaminase inhibitor (telaglenastat) to standard chemoradiation helps people with advanced cervical cancer live longer without the disease getting worse. About 42 adults with stage III–IVA cervical cancer will receive the drug alongside standard…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a targeted pill clear hidden lung cancer cells after surgery?
Disease control Not yet recruitingThis phase 2 trial tests whether zipalertinib, an oral drug that targets cancer cells with atypical EGFR mutations, can eliminate remaining cancer cells in people with early-stage non-small cell lung cancer. Participants who have completed standard treatment and show signs of min…
Phase 2 • Sponsor: Stanford University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a targeted drug duo boost the power of surgery for stomach cancer?
Disease control Not yet recruitingThis trial tests whether combining two targeted therapies, with or without chemotherapy, can improve outcomes for people with resectable stomach or gastroesophageal junction cancer. Participants receive the treatment before and after surgery to remove the tumor. The main goal is …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can adding immunotherapy to standard cancer care be safe for indian patients?
Disease control Not yet recruitingThis trial tests whether pembrolizumab, an immunotherapy drug, is safe when combined with chemotherapy or chemoradiotherapy for people in India with advanced gastric or gastroesophageal junction cancer, advanced biliary tract cancer, or high-risk locally advanced cervical cancer.…
Phase 4 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Triple-Drug combo outsmart pancreatic cancer?
Disease control Not yet recruitingThis trial tests whether adding an experimental immunotherapy (SHR-1701) and a targeted drug (apatinib) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with advanced pancreatic cancer. The study enrolls adults aged 18 to 75 who have not yet received trea…
Phase 1/2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug duo aims to outperform chemo in ovarian cancer
Disease control Not yet recruitingThis phase 3 trial tests whether a new drug called mocertatug rezetecan (Mo-Rez) combined with bevacizumab works better than standard chemotherapy plus bevacizumab for women with platinum-sensitive ovarian cancer. The study includes about 690 participants whose cancer has returne…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can adding a hormone pill to chemotherapy shrink breast tumors better before surgery?
Disease control Not yet recruitingThis phase II trial tests whether combining the hormone therapy letrozole with standard chemotherapy before surgery can improve tumor shrinkage in people with ER-positive, HER2-negative breast cancer that grows quickly. Participants receive either six cycles of docetaxel, epirubi…
Phase 2 • Sponsor: The Second Hospital of Anhui Medical University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a coordinated care team reduce severe side effects in older cancer patients?
Disease control Not yet recruitingThis trial tests whether a coordinated care pathway, involving oncologists, geriatricians, pharmacists, and pharmacologists, can reduce severe side effects in adults over 70 with certain cancers who are starting oral therapy. Participants receive extra monitoring, including blood…
Phase 4 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can adding capivasertib slow metastatic breast cancer?
Disease control Not yet recruitingThis trial tests whether adding the investigational drug capivasertib to standard hormone-blocking therapy and a CDK4/6 inhibitor can improve treatment response in people with HR-positive, HER2-negative metastatic breast cancer. Participants receive either the standard treatment …
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Two-Drug combo outperform standard care in aggressive lung cancer?
Disease control Not yet recruitingThis phase III trial compares an experimental combination of two drugs, QLC5508 and QL2107, against the current standard treatment (tislelizumab plus chemotherapy) as a first-line therapy for people with extensive-stage small cell lung cancer. The study enrolls adults who have no…
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Triple-Drug cocktail aims to shrink head and neck tumors
Disease control Not yet recruitingThis study tests whether adding a targeted drug (cetuximab) to standard immunotherapy (pembrolizumab or finotonlimab) and chemotherapy helps people with advanced head and neck cancer live longer without their cancer growing. About 316 adults aged 18-70 with cancer that has spread…
Phase 3 • Sponsor: Ji Dongmei • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Personalized drug matching put to the test in pancreatic cancer
Disease control Not yet recruitingThis phase 2 trial tests whether choosing treatment based on the genetic changes in a person's pancreatic cancer works better than standard chemotherapy. Adults with advanced pancreatic cancer that has progressed after first-line treatment may join if their tumor has a genetic ch…
Phase 2 • Sponsor: Herlev Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Two-Drug combo keep Limited-Stage lung cancer at bay?
Disease control Not yet recruitingThis phase 2 trial tests whether combining an experimental drug called SHR-7787 with the immunotherapy adebrelimab can help people with limited-stage small cell lung cancer. The study enrolls adults aged 18 to 75 whose cancer has not progressed after standard chemotherapy and rad…
Phase 2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new drug combo shrink metastatic colorectal tumors?
Disease control Not yet recruitingThis trial tests whether an experimental drug called LBL-024, when combined with standard treatments like bevacizumab, oxaliplatin, capecitabine, or fruquintinib, can safely shrink tumors in people with metastatic colorectal cancer. The study includes adults aged 18 to 75 who hav…
Phase 1/2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New bladder cancer drug could spare patients from bladder removal
Disease control Not yet recruitingThis Phase 3 trial tests NDV-01, a sustained-release combination of two chemotherapy drugs (gemcitabine and docetaxel), given directly into the bladder. It aims to prevent cancer from coming back in people with non-muscle invasive bladder cancer, including those who have not resp…
Phase 3 • Sponsor: Relmada Therapeutics, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for hard-to-treat colorectal cancer? early trial launches
Disease control Not yet recruitingThis early-phase trial tests two immunotherapy drugs (ivonescimab and ADG126) alone or with chemotherapy in 30 adults with advanced or metastatic MSS colorectal cancer, a type that doesn't respond well to standard immunotherapy. The main goal is to find safe doses and check for s…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Tumor-Directed injection shrink Hard-to-Treat cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called HP007, given as an injection directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments or have come back. The main goals are to check the drug's safety, find the right dose…
Phase 1 • Sponsor: Parr Biotechnology (Hebei) Co., Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New voice valve could cut down on annoying replacements for throat cancer survivors
Disease control Not yet recruitingThis study tests whether using the Provox ActiValve voice prosthesis as a first choice can reduce the number of times the device needs to be replaced each year in people who have had their voice box removed (laryngectomy) and have a tracheoesophageal puncture (TEP). The trial wil…
Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Smart patch and app aim to boost lung recovery after cancer surgery
Disease control Not yet recruitingThis trial tests whether a wireless wearable monitor (chest patch or wristband) plus a smartphone-based rehab program can help people recover lung function after surgery for non-small cell lung cancer. Participants who have had curative-intent surgery will either receive standard…
Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a two-drug combo outsmart resistant lung cancer?
Disease control Not yet recruitingThis phase 1 trial tests whether combining an experimental oral drug, JIN-A02, with an existing intravenous drug, amivantamab, is safe and can shrink tumors in people with advanced EGFR-mutant non-small cell lung cancer that has progressed after treatment with a third-generation …
Phase 1 • Sponsor: Yonsei University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo aims to fight merkel cell cancer when immunotherapy fails
Disease control Not yet recruitingThis study tests whether combining two drugs—ASTX727 (a pill) and retifanlimab (given through a vein)—can shrink tumors and control advanced Merkel cell cancer in people whose disease has worsened after standard immunotherapy. About 31 adults with stage III or IV Merkel cell canc…
Phase 1/2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can sound waves supercharge immunotherapy against bile duct cancer?
Disease control Not yet recruitingThis trial is testing whether adding a non-invasive ultrasound treatment called histotripsy to the immunotherapy drug durvalumab can strengthen the body's immune response against advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer. Histotripsy uses focused sound …
Phase 2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
At-Home HPV tests could save lives of women with HIV
Disease control Not yet recruitingThis study looks at whether giving women living with HIV the option to collect their own HPV test samples at home or in their community, with help from health workers, increases how many get screened for cervical cancer. About 17,700 women will take part across multiple clinics. …
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail targets rare liver cancer in 29-Patient trial
Disease control Not yet recruitingThis study tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) plus chemotherapy (gemcitabine and cisplatin) in people with a rare, advanced liver cancer called combined hepatocellular-cholangiocarcinoma that cannot be removed by surgery or has spread. Ab…
Phase 2 • Sponsor: Mehmet Akce • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a Triple-Drug combo shrink esophageal tumors before surgery?
Disease control Not yet recruitingThis trial tests whether giving a combination of immunotherapy (sintilimab) and two chemotherapy drugs (paclitaxel polymeric micelles and cisplatin) before surgery can help people with a certain type of esophageal cancer. The treatment aims to shrink tumors and improve the chance…
Phase 2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Experimental drug duo aims to boost immune attack on tough cancers
Disease control Not yet recruitingThis study tests a combination of two experimental drugs, obrixtamig and ZL-1310, designed to help the immune system fight cancer. It is for adults with advanced small cell lung cancer or other neuroendocrine cancers. The trial has two parts: the first finds a safe dose of the tw…
Phase 1/2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo therapy targets hard-to-treat lung cancer mutation
Disease control Not yet recruitingThis study tests whether adding a cancer vaccine (CIMAVAX-EGF) to standard targeted drugs (sotorasib or adagrasib) can help control advanced lung cancer with a KRAS G12C mutation. About 29 adults with stage III or IV non-small cell lung cancer will receive the combination. The go…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New pill shows promise for tough bladder cancer cases
Disease control Not yet recruitingThis study tests an experimental daily pill called zanzalintinib in 44 adults with advanced bladder cancer that has continued to grow after previous treatments. The goal is to see if the drug can shrink tumors or slow the cancer's progression. Participants will take the pill once…
Phase 2 • Sponsor: Guru Sonpavde • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
A Spleen-Saving surgery for pancreatic cancer faces its biggest test
Disease control Not yet recruitingThis trial compares two surgical approaches for people with pancreatic cancer in the left side of the pancreas. One method removes the spleen along with the tumor, which is standard practice. The other preserves the spleen, potentially reducing complications and avoiding lifelong…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo aims to stall endometrial cancer
Disease control Not yet recruitingThis phase 3 trial tests whether adding an experimental drug (GSK5733584) to standard immunotherapy can help keep advanced or recurrent endometrial cancer from growing. About 610 adults who have already completed initial chemotherapy with immunotherapy will receive either the new…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a Two-Pronged drug attack Hard-to-Treat tumors?
Disease control Not yet recruitingThis first-in-human trial tests an experimental drug called BD200 in adults with advanced solid tumors that have not responded to standard treatments. BD200 is designed to latch onto two proteins, Trop-2 and Nectin-4, found on many cancer cells, potentially delivering a toxic pay…
Phase 1 • Sponsor: Biolojic Design Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Wearable tech and digital rehab may shorten recovery between lung cancer surgeries
Disease control Not yet recruitingThis trial tests whether a digital rehabilitation program, combined with wireless wearable monitors, can help people recover faster between two planned lung cancer surgeries. Participants with multiple primary non-small cell lung cancer will be randomly assigned to either standar…
Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can radiation spare the brain while fighting cancer in the spinal fluid?
Disease control Not yet recruitingThis trial tests a type of radiation called brain-avoidant proton craniospinal irradiation (BRAVO-pCSI) in people with leptomeningeal metastases, a condition where cancer spreads to the fluid and lining around the brain and spinal cord. The study includes adults with breast cance…
Phase 2 • Sponsor: University of Miami • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a targeted drug duo hold off ovarian cancer's return?
Disease control Not yet recruitingThis trial tests whether raludotatug deruxtecan, given alone or with bevacizumab, can delay cancer growth better than standard care in people with platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer that has returned after first treatment. About 600 adults as…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new drug boost chemotherapy for a rare cancer?
Disease control Not yet recruitingThis phase III trial is testing whether adding an experimental drug called LBL-024 to standard chemotherapy can help people with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC), a rare and aggressive cancer. Participants will receive either LBL-024 or a placebo alongsid…
Phase 3 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new drug outperform chemotherapy in Hard-to-Treat cervical cancer?
Disease control Not yet recruitingThis trial compares an experimental drug called JSKN033 with standard chemotherapy in people whose cervical cancer has returned or spread and no longer responds to platinum-based chemotherapy or PD-1/L1 inhibitors. The study includes about 368 adults with recurrent or metastatic …
Phase 3 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New MRI technique aims to spare healthy lung during cancer radiation
Disease control Not yet recruitingThis early-phase trial tests whether a special MRI scan using hyperpolarized xenon gas can help doctors plan radiation treatment for non-small cell lung cancer. The goal is to deliver enough radiation to the tumor while avoiding healthy lung tissue, which could reduce side effect…
Phase 1/2 • Sponsor: Xemed LLC • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a steroid given during pancreatic surgery prevent a dangerous leak?
Disease control Not yet recruitingThis trial tests whether giving hydrocortisone during and right after pancreatic surgery can lower the risk of a postoperative pancreatic fistula, a serious leak of digestive fluids. About 20 adults with pancreatic, duodenal, or bile duct cancer will be randomly assigned to recei…
Phase 1 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new drug rally the immune system against Hard-to-Treat cancers?
Disease control Not yet recruitingThis early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a targeted drug outperform chemotherapy for stomach cancer?
Disease control Not yet recruitingThis trial tests whether an experimental drug called ATG-022 can slow the growth of advanced stomach or gastroesophageal junction cancer better than standard chemotherapy. The study enrolls adults whose tumors show a specific marker called CLDN18.2 and who have already tried at l…
Phase 3 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a primer drug make chemotherapy work better for frail head and neck cancer patients?
Disease control Not yet recruitingThis phase 2 trial tests whether giving toripalimab first can prime head and neck cancer tumors to respond better to the chemotherapy drug paclitaxel. The study enrolls 22 patients with metastatic or incurable head and neck squamous cell carcinoma who have a reduced performance s…
Phase 2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a drug combo replace chemo before breast cancer surgery?
Disease control Not yet recruitingThis phase II trial tests whether a combination of culmerciclib, letrozole, trastuzumab, and pertuzumab can shrink tumors before surgery in people with HR-positive, HER2-positive early or locally advanced breast cancer. About 33 participants who have not had prior treatment will …
Phase 2 • Sponsor: Shengjing Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug cocktail aims to shrink oral tumors before surgery
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs, XL-092 and pembrolizumab (Keytruda), given before surgery to people with a type of oral cancer that is HPV-negative and can be removed. The goal is to see if the drugs can shrink or eliminate the tumor before the operation. Abo…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a new Immune-Boosting drug shrink advanced solid tumors?
Disease control Not yet recruitingThis Phase 2 trial tests an investigational drug called MK-2010, which is designed to help the immune system attack cancer. Researchers will give MK-2010 alone or in combination with other treatments to about 480 people with advanced solid tumors, meaning cancers that have spread…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a targeted drug combo outperform standard care for aggressive lung cancer?
Disease control Not yet recruitingThis phase 3 trial tests whether the experimental drug ZL-1310, when combined with an immunotherapy drug, can help people with extensive-stage small cell lung cancer live longer than those receiving standard chemotherapy plus immunotherapy. The study enrolls about 530 adults who …
Phase 3 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a Platinum-Free regimen beat nasopharyngeal carcinoma?
Disease control Not yet recruitingThis phase II trial tests a new treatment approach for people with locally advanced nasopharyngeal carcinoma, a type of head and neck cancer. The regimen avoids platinum-based chemotherapy, using a combination of gemcitabine, camrelizumab, endostar, and low-dose radiotherapy befo…
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a Pan-RAS inhibitor outsmart pancreatic cancer?
Disease control Not yet recruitingThis trial is testing whether a new oral drug called HRS-2329, which blocks multiple RAS proteins, can shrink tumors or slow disease when combined with other anti-cancer therapies. It is enrolling adults with advanced pancreatic cancer that has RAS mutations or amplifications and…
Phase 1/2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a radioactive injection extend life in advanced prostate cancer?
Disease control Not yet recruitingThis phase III trial tests whether adding a radioactive drug called 177Lu-NYM032 to standard care helps men with a specific type of advanced prostate cancer live longer. The drug targets a protein called PSMA found on many prostate cancer cells, delivering radiation directly to t…
Phase 3 • Sponsor: Norroy Bioscience Co., LTD • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can a smart chemo drug outsmart advanced throat cancer?
Disease control Not yet recruitingThis trial is testing whether CRB-701, a targeted chemotherapy that delivers a potent drug directly to cancer cells, can shrink tumors and extend life in people with recurrent or metastatic oropharyngeal (throat or tonsil) cancer. Participants will have already tried platinum-bas…
Phase 3 • Sponsor: Corbus Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can clot removal help even the largest strokes?
Disease control Not yet recruitingThis trial tests whether a procedure to remove blood clots from the brain, called endovascular treatment, can improve recovery in people who have had a severe stroke with a very large area of brain damage. Participants receive either the clot-removal procedure plus standard medic…
Sponsor: First Affiliated Hospital of Harbin Medical University • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a daily mineral make liver cancer therapy work better?
Disease control Not yet recruitingThis trial tests whether adding daily oral zinc to standard targeted therapy and immunotherapy helps people with advanced liver cancer. About 60 participants will be randomly assigned to receive the standard treatment alone or with either 20 mg or 30 mg of zinc each day. The main…
Phase 2 • Sponsor: Anhui Provincial Hospital • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Ancient herbal mix could boost liver health in advanced cancer
Disease control Not yet recruitingThis trial tests whether adding a Chinese herbal formula called Shuganhuazhuo to standard anti-cancer therapy can improve liver function and survival in people with advanced hepatocellular carcinoma (the most common type of liver cancer). The study includes 120 adults who are abo…
Phase 2 • Sponsor: Xiang-Qian • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a Two-Pronged immune attack outsmart stomach cancer?
Disease control Not yet recruitingThis Phase 2 trial is testing whether rilvegostomig, an experimental immunotherapy that blocks two immune-suppressing pathways (PD-1 and TIGIT), can produce a stronger immune response against advanced gastric cancer than the standard single-target drug pembrolizumab. About 50 peo…
Phase 2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Two-Drug chemo combo outsmart resistant tumors?
Disease control Not yet recruitingThis early-stage trial is testing whether combining two chemotherapy drugs—liposomal irinotecan and cisplatin—can safely shrink or control advanced solid tumors that have not responded to standard treatments. The study will enroll about 44 adults aged 20 to 85 with various types …
Phase 1 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Exercise as a cancer ally: could a bike ride supercharge immunotherapy?
Disease control Not yet recruitingThis trial tests whether a structured exercise program can strengthen the immune system's attack on non-small cell lung cancer. Patients receiving chemo-immunotherapy before surgery will either follow an exercise plan with a stationary bike or receive standard recommendations. Th…
Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Pre-Surgery drug combo wipe out early breast cancer?
Disease control Not yet recruitingThis trial is testing whether giving a combination of immunotherapy (pembrolizumab) and chemotherapy before surgery can shrink or eliminate tumors in people with stage I triple-negative breast cancer. The study compares different treatment regimens to see which is most effective …
Phase 2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Dye-Guided surgery may spare healthy lymph nodes in esophageal cancer
Disease control Not yet recruitingThis trial tests whether using a dye to identify and remove only the sentinel lymph nodes (the first nodes cancer might spread to) during esophageal cancer surgery is as effective as removing all nearby lymph nodes. The study includes 200 adults with early-stage esophageal squamo…
Phase 3 • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Less may be more: smaller lung surgery tested against standard for early cancer
Disease control Not yet recruitingThis phase 3 trial compares two surgical approaches for early-stage non-small cell lung cancer with small (≤2 cm), solid-dominant tumors located deep within the lung. One group receives segmentectomy, which removes only the affected segment of the lung, while the other receives l…
Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a targeted therapy tame hard-to-treat stomach and esophageal cancers?
Disease control Not yet recruitingThis study looks at how zanidatamab, a targeted drug for HER2-positive gastroesophageal cancer, is used in real-world clinical practice. Researchers will track about 300 adults with advanced or metastatic disease who are starting zanidatamab as their first treatment, recording pa…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a RAGE inhibitor revive a failing breast cancer treatment?
Disease control Not yet recruitingThis trial is testing whether adding azeliragon, a RAGE inhibitor, to the drug T-DXd can help people with HER2-positive or HER2-low metastatic breast cancer whose cancer has progressed despite prior T-DXd treatment. The study will first find the safest dose of the combination, th…
Phase 1/2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Smart scans may slash radiation doses for metastatic prostate cancer
Disease control Not yet recruitingThis early-phase trial explores whether PSMA PET scans can help doctors adjust radiation therapy for men with prostate cancer that has spread to 4 to 20 spots in the body. Participants receive standard hormone therapy plus a special PET scan, then targeted radiation to all visibl…
Early phase 1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
AI uncovers hidden target: could a powerful drug shrink 'HER2-Null' breast tumors?
Disease control Not yet recruitingThis trial is testing whether the drug trastuzumab deruxtecan (T-DXd) can help people with a certain type of advanced breast cancer. The study focuses on patients whose tumors were originally classified as HER2-null (no HER2 protein) but were re-scored as HER2-ultralow using arti…
Sponsor: Shuangyue Liu • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a Weight-Loss drug boost Fertility-Sparing cancer treatment?
Disease control Not yet recruitingThis trial tests whether adding mazdutide, a weekly injection that helps with weight loss, to a hormonal intrauterine device (IUD) can improve treatment for overweight or obese women with atypical endometrial hyperplasia or early-stage endometrioid endometrial cancer who wish to …
Phase 2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Radiation boost may extend Drug-Free time in prostate cancer recurrence
Disease control Not yet recruitingThis trial tests whether adding targeted radiation to standard hormone therapy can help men with recurring prostate cancer stay off cancer drugs longer. Men with a rising PSA and 1 to 5 metastases will receive either hormone therapy alone or hormone therapy plus radiation to the …
Phase 3 • Sponsor: Ente Ospedaliero Cantonale, Bellinzona • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Weight-Loss drug may rescue lung cancer treatment from metabolic side effects
Disease control Not yet recruitingThis trial tests whether tirzepatide, a medication used for weight management, can reduce the rapid weight gain and metabolic changes caused by lorlatinib, a targeted therapy for ALK-positive non-small cell lung cancer. Adults already taking lorlatinib will receive weekly tirzepa…
Phase 1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a Direct-to-Brain chemo route outsmart resistant lung cancer?
Disease control Not yet recruitingThis phase II trial is testing whether giving the chemotherapy drug thiotepa directly into the spinal fluid—via a small device called an Ommaya reservoir—can help control cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastases) in people with …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a new drug take on multiple tough cancers?
Disease control Not yet recruitingThis early-stage trial tests an investigational drug called CBX-663 in adults with certain advanced cancers that have not responded to standard treatment or have returned. The study includes people with blood cancers (like AML, MDS, or CMML), advanced solid tumors, or a type of b…
Phase 1 • Sponsor: Crossbow Therapeutics, Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a drug combo prime the immune system to fight kidney cancer before surgery?
Disease control Not yet recruitingThis phase II trial is testing whether giving toripalimab (an immunotherapy) plus axitinib (a targeted therapy) for about 12 weeks before a possible delayed kidney removal can help control advanced clear cell kidney cancer. The study enrolls adults whose primary kidney tumor is s…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can an Anti-Inflammatory drug make liver cancer immunotherapy safer?
Disease control Not yet recruitingThis phase II trial is testing whether adding tocilizumab, an anti-inflammatory drug, to a standard two-drug immunotherapy regimen can reduce severe immune-related side effects in people with advanced liver cancer. The study enrolls about 51 adults with hepatocellular carcinoma t…
Phase 2 • Sponsor: CHA University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can freezing breast tumors replace the scalpel?
Disease control Not yet recruitingThis trial is investigating whether cryoablation, a technique that freezes and destroys breast tumors with extreme cold, can be an effective alternative to surgery for certain patients. The study will include adults with localized breast cancer who cannot or choose not to have su…
Sponsor: Ospedale Cottolengo • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Smartwatch-Guided prehab aims to boost pancreatic surgery recovery
Disease control Not yet recruitingThis trial tests whether a wearable device and a personalized prehabilitation program can help adults recover better after surgery for pancreatic cancer or related conditions. Participants will wear a monitor to track vital signs and activity, and follow a program of exercise, nu…
Sponsor: Manchester University NHS Foundation Trust • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a One-Two punch of immunotherapy and radiation wipe out head and neck tumors before surgery?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining the immunotherapy drug pembrolizumab with a short course of high-dose radiation, with or without additional radiation to nearby lymph nodes, can shrink or eliminate head and neck tumors before surgery. Adults with resectable squamou…
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can adding immunotherapy to HER2 therapy erase more tumors?
Disease control Not yet recruitingThis trial tests whether adding an immunotherapy drug called retifanlimab to two standard HER2-targeted therapies (trastuzumab and pertuzumab) can improve treatment response in people with HER2-positive breast cancer. The main goal is to see if the combination leads to a complete…
Phase 2 • Sponsor: Polly A. Niravath, MD • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can adding immunotherapy to chemotherapy keep stomach cancer at bay?
Disease control Not yet recruitingThis trial is testing whether adding the immunotherapy drug serplulimab to a standard chemotherapy regimen (SOX) after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. The study includes adults with stage II-III cancer whose tumors show certa…
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can switching cancer therapy early extend life in stomach cancer?
Disease control Not yet recruitingThis trial is testing whether switching to a different drug combination after initial chemotherapy can help people with advanced gastroesophageal cancer live longer without the disease worsening. Participants first receive standard chemotherapy plus an immunotherapy drug (tisleli…
Phase 3 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can an immunotherapy combo turn inoperable gallbladder cancer into a surgical success?
Disease control Not yet recruitingThis phase II trial is testing whether adding an experimental immunotherapy drug called AK112 to a standard chemotherapy regimen (gemcitabine, cisplatin, and albumin-bound paclitaxel) can shrink locally advanced gallbladder tumors enough to allow surgery. Adults with gallbladder …
Phase 2 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a Bag-Like device pull bladder tumors out whole?
Disease control Not yet recruitingThis trial tests a new tool called CURTIS, designed to safely remove bladder tumors in one intact piece after they are cut out during surgery. The goal is to see how often the device can successfully retrieve the tumor without breaking it apart, and what the largest tumor size is…
Sponsor: Ludwig-Maximilians - University of Munich • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can AI-Guided home training boost recovery from gastric cancer surgery?
Disease control Not yet recruitingThis trial tests whether a home-based prehabilitation program, supported by 5G and artificial intelligence, can help gastric cancer patients prepare for surgery after chemotherapy. The program includes personalized exercise, nutrition, and psychological support, all supervised re…
Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
Disease control Not yet recruitingThis phase 2 trial is testing whether combining two immunotherapy drugs—vilastobart and retifanlimab—can shrink tumors in people with metastatic pancreatic cancer that has a BRCA1, BRCA2, or PALB2 gene mutation. Participants receive both drugs by IV infusion over several months. …
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can diet and vitamin c supercharge rectal cancer treatment?
Disease control Not yet recruitingThis phase 2 trial is investigating whether adding a ketogenic diet and/or high-dose intravenous vitamin C to standard chemoradiotherapy and immunotherapy can improve outcomes for patients with locally advanced rectal cancer that is mismatch repair proficient (pMMR/MSS). The stud…
Phase 2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a Hormone-Blocking drug boost chemo against cervical cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding relacorilant—a drug that blocks a stress-related hormone—to the chemotherapy nab-paclitaxel can shrink tumors in people with recurrent or metastatic cervical cancer. Participants have already tried platinum-based chemo and immunotherap…
Phase 2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Blood test may tailor lung cancer immunotherapy, sparing unnecessary treatment
Disease control Not yet recruitingThis trial is testing whether a blood test that detects cancer DNA can guide the use of durvalumab, an immunotherapy, after standard chemoradiotherapy in patients with stage III lung cancer that cannot be removed by surgery. The goal is to see if giving durvalumab only to patient…
Phase 2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a drug combo outsmart a tough breast cancer subtype?
Disease control Not yet recruitingThis phase III trial is testing whether adding everolimus to trastuzumab rezetecan helps people with a specific subtype of triple-negative breast cancer (called luminal androgen receptor) live longer without their disease progressing. The study enrolls adults with advanced or met…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy (FLOT before surgery, TS-1 after) can improve outcomes for people with resectable gastric or gastroesophageal junction cancer. The study aims to see if this combination increas…
Phase 2 • Sponsor: Taipei Veterans General Hospital, Taiwan • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can less radiation be just as effective for early breast cancer?
Disease control Not yet recruitingThis trial is testing whether treating only part of the breast with radiation is as effective as treating the whole breast in women with early-stage, low-risk breast cancer. Participants are women aged 40 and older who had breast-conserving surgery and did not have a sentinel lym…
Phase 3 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Virtual patients could revolutionize cancer drug testing
Disease control Not yet recruitingThis trial is testing whether artificial intelligence can create 'digital twin' models of esophageal cancer patients to predict how they will respond to a combination of immunotherapy and chemotherapy. The study will compare the AI's predictions against real outcomes in patients …
Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
PET scans may predict which breast cancer patients benefit from elacestrant
Disease control Not yet recruitingThis trial is testing whether a special PET scan can help predict how well the drug elacestrant works in people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has not responded to prior hormone therapy. All participants will take elacestrant daily…
Phase 2 • Sponsor: Jules Bordet Institute • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Two-Pronged radiation strategy boost immunotherapy against advanced nasopharyngeal cancer?
Disease control Not yet recruitingThis trial is testing whether a special type of radiation called radscopal radiotherapy—which combines low-dose radiation to the main tumor and precise high-dose radiation to distant metastases—can enhance the effects of two immunotherapy drugs (sintilimab and ipilimumab) in peop…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can immunotherapy boost surgery outcomes in recurrent head and neck cancer?
Disease control Not yet recruitingThis trial is testing whether adding an immunotherapy drug (PD-1 antibody) to standard treatment can improve outcomes for people with recurrent head and neck cancer. Participants will be randomly assigned to receive either the immunotherapy before and after surgery, or standard s…
Phase 2 • Sponsor: Yanjie Zhang, MD • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a targeted drug shrink Hard-to-Treat thymic tumors?
Disease control Not yet recruitingThis phase II trial is testing whether an experimental drug called sacituzumab tirumotecan (Sac-TMT) can shrink tumors in people with thymic carcinoma that cannot be surgically removed and has already been treated with platinum-based chemotherapy. Participants receive the drug in…
Phase 2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
Disease control Not yet recruitingThis phase 3 trial is testing whether giving four cycles of chemotherapy combined with targeted therapy (trastuzumab and pertuzumab) before surgery works as well as the standard six cycles for people with intermediate-risk HER2-positive breast cancer. The goal is to see if a shor…
Phase 3 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can matching cancer drugs to tumor genes prevent biliary tract cancer return?
Disease control Not yet recruitingThis phase 3 trial is testing whether giving targeted therapies that match specific genetic abnormalities in a person's tumor can delay or prevent biliary tract cancer from coming back after surgery. Participants will have their tumor tested for certain markers, and if found, the…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Blood test may let cancer patients take safe breaks from immunotherapy
Disease control Not yet recruitingThis trial investigates whether a sensitive blood test (Signatera) can detect when it is safe to pause immunotherapy in people with advanced solid tumors like lung cancer, melanoma, and colorectal cancer. Participants are randomly assigned to either continuous standard immunother…
Sponsor: Natera, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding an investigational drug called ivonescimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. Ivonescimab is a bispecific antibody that works in two ways: it helps the immune sys…
Phase 2 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a targeted radiation boost slow advanced lung cancer?
Disease control Not yet recruitingThis trial is testing whether giving radiotherapy to the main lung tumour, in addition to standard chemotherapy or immunotherapy, can reduce cancer spread and help people with metastatic non-small-cell lung cancer live longer. Around 420 adults with newly diagnosed stage IV lung …
Phase 3 • Sponsor: Trans Tasman Radiation Oncology Group • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Ovarian suppression plus tamoxifen: a Long-Term bet against breast cancer recurrence
Disease control Not yet recruitingThis study follows young women with hormone-sensitive breast cancer who stayed premenopausal or resumed menstruation after chemotherapy. Researchers are investigating whether adding two years of ovarian function suppression to standard tamoxifen therapy can lower the chance of ca…
Sponsor: MedicalExcellence • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a Triple-Drug cocktail turn inoperable liver cancer into a surgical target?
Disease control Not yet recruitingThis trial is testing whether a combination of two newer drugs—envafolimab and suvemcitug—plus chemotherapy delivered directly to the liver can shrink advanced liver tumors enough to allow surgery. The study enrolls adults aged 18–75 with liver cancer that is currently too advanc…
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a sound wave boost prostate cancer radiation precision?
Disease control Not yet recruitingThis trial is testing whether using microultrasound to guide a radiation boost to cancerous spots inside the prostate can reduce side effects compared to standard radiation therapy. Men with intermediate-risk prostate cancer will receive stereotactic body radiation therapy (SBRT)…
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Preventive radiation may stop bone events before they start — a trial puts it to the test
Disease control Not yet recruitingThis phase 3 trial tests whether giving radiation therapy early — before symptoms appear — can reduce the risk of bone complications (like fractures or spinal cord pressure) in people with solid tumors that have spread to the bone. Participants have bone lesions that are consider…
Phase 3 • Sponsor: Centre Henri Becquerel • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a Patient's own immune cells be trained to fight advanced GI cancers?
Disease control Not yet recruitingThis early trial is testing an experimental cell therapy called cCTL-GL01 in people with advanced stomach, esophageal, colon, or rectal cancers that have not responded to standard treatments. The therapy uses a patient's own immune cells, which are specially trained in the lab to…
Phase 1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
AI-Powered surveillance may outsmart liver cancer recurrence
Disease control Not yet recruitingThis trial tests whether an artificial intelligence system can tailor the timing of follow-up scans for people who have had liver cancer surgically removed or ablated. Instead of fixed-interval scans every four months, the AI uses routine clinical data to estimate each person's c…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a new drug combo slow advanced prostate cancer?
Disease control Not yet recruitingThis trial is investigating whether an experimental drug called XNW5004, when combined with standard anti-tumor therapies, can help control advanced prostate cancer. The study involves men with prostate cancer that has spread. Researchers are looking at how safe the combination i…
Phase 2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a gentler drug trio tame small cell lung cancer in older patients?
Disease control Not yet recruitingThis trial is testing a combination of three drugs—benmelstobart, anlotinib, and etoposide—as a first treatment for elderly patients (65 and older) or those too frail for standard intensive chemotherapy. The goal is to see if this platinum-free regimen can control the cancer and …
Phase 3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
AI takes on liver cancer: could a computer help pick the right immunotherapy?
Disease control Not yet recruitingThis trial tests whether an artificial intelligence (AI) system can help doctors select the best first-line immune checkpoint inhibitor (ICI) therapy for adults with unresectable hepatocellular carcinoma (HCC), a type of advanced liver cancer. About 1,800 participants across 26 h…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
AI eye on bladder cancer: could a smart navigation system help surgeons remove tumors more completely?
Disease control Not yet recruitingThis trial tests whether an artificial intelligence system can help surgeons better see and remove bladder tumors during a standard procedure called TURBT. The AI analyzes the live video from the surgical camera and highlights suspicious areas and recommended cutting edges on the…
Sponsor: Fudan University • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can two immune boosters outsmart Chemo-Resistant colon cancer?
Disease control Not yet recruitingThis phase 3 trial is testing whether adding two immune-boosting drugs, iparomlimab and tuvonralimab, to standard chemotherapy can help people with a specific type of metastatic colorectal cancer that has stopped responding to first-line treatment. The study includes about 270 ad…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Electric pulses and diet: a new weapon against muscle loss in stomach and bowel cancers?
Disease control Not yet recruitingThis trial tests whether a combination of whole-body electromyostimulation (WB-EMS) — a technology that uses electrical impulses to make muscles contract — and nutritional therapy can help people with certain gastrointestinal cancers preserve muscle mass. Participants include tho…
Sponsor: University of Cologne • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can adding chemo after radiation help older adults with rectal cancer avoid surgery?
Disease control Not yet recruitingThis phase 3 trial is testing whether adding a three-month course of FOLFOX4s chemotherapy after short-course radiotherapy improves outcomes compared to radiotherapy alone in adults aged 75 and older with locally advanced rectal cancer. The study aims to see if the combination ca…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Real-World check: can a targeted ovarian cancer drug deliver outside clinical trials?
Disease control Not yet recruitingThis study tracks the safety and effectiveness of mirvetuximab soravtansine (MIRV), a drug that targets a protein called folate receptor alpha on cancer cells, in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. Researchers will observe 400 patients r…
Sponsor: NING LI-GYN • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Less radiation for breast cancer? a trial tests a smarter, response-based approach
Disease control Not yet recruitingThis trial is investigating whether women with node-positive breast cancer whose lymph nodes are cancer-free after chemotherapy can safely receive less extensive radiation. Instead of radiating the entire lymph node region, the study compares standard radiation to a more targeted…
Sponsor: Aya Ahmed Sayed • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Experimental drug targets rare genitourinary cancers in new trial
Disease control Not yet recruitingThis phase 2 trial tests an experimental drug called sacituzumab tirumotecan in people with two rare types of cancer: papillary renal carcinoma and less common forms of bladder cancer. The drug is given by IV every two weeks for up to three years. The main goal is to see how many…
Phase 2 • Sponsor: Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug sequence aims to outsmart advanced breast cancer
Disease control Not yet recruitingThis trial tests a planned sequence of treatments for people with advanced or metastatic HER2-positive and hormone receptor-positive breast cancer. Participants first receive T-DXd (Enhertu) plus pertuzumab, then switch to a maintenance combination of palbociclib, endocrine thera…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can early tumor response guide smarter cancer treatment?
Disease control Not yet recruitingThis phase II trial tests a personalized approach for people with locally advanced esophageal cancer. After initial chemoimmunotherapy, patients whose tumors shrink well go straight to surgery, while those with less response receive additional radiotherapy before surgery. The goa…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a TROP2-targeting drug shrink hard-to-treat small bowel cancer?
Disease control Not yet recruitingThis phase II trial tests whether sacituzumab tirumotecan, an antibody-drug conjugate that targets the TROP2 protein, can shrink tumors in people with advanced small bowel adenocarcinoma that has worsened after platinum-based chemotherapy. About 27 adults with this rare cancer wi…
Phase 2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a triple threat of drug, immunotherapy, and radiation wipe out High-Risk urinary tract cancer before surgery?
Disease control Not yet recruitingThis phase 2 trial is testing whether a combination of an antibody-drug conjugate (disitamab vedotin), an immunotherapy (toripalimab), and targeted radiation can improve outcomes for people with high-risk upper tract urothelial carcinoma. Participants receive the drug and immunot…
Phase 2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New 'WARNING Pack' aims to protect quality of life in older cancer patients
Disease control Not yet recruitingThis trial tests a care package called the 'WARNING Pack' for people aged 75 and older with cancer. The pack helps doctors spot early signs of age-related problems and provides a guide for managing them. The goal is to prevent a decline in quality of life and reduce the risk of g…
Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could chemo plus immunotherapy double the punch against tough lung cancers?
Disease control Not yet recruitingThis phase 3 trial investigates whether adding platinum-based chemotherapy to the immunotherapy drug tislelizumab helps people with a specific type of advanced lung cancer live longer without the disease worsening. Participants have non-small cell lung cancer that has spread, sho…
Phase 3 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Real-World data may reveal Pluvicto's true impact on advanced prostate cancer survival
Disease control Not yet recruitingThis study looks at how effective the drug Pluvicto (177Lu-PSMA-617) is in treating men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. Researchers will analyze medical records from over 1,000 patients …
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer
Disease control Not yet recruitingThis study tests whether adding a new oral drug called fulvestaciclib to standard anti-HER2 and hormone therapy can help people with HR+/HER2+ advanced breast cancer live longer without their disease getting worse. Some participants receive the combo after initial chemotherapy, w…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Blood test could signal when to switch breast cancer therapy before tumors grow
Disease control Not yet recruitingThis phase 3 trial tests whether monitoring tumor DNA in the blood (ctDNA) can help doctors switch hormone therapy earlier in people with ER+/HER2- metastatic breast cancer. Participants whose ctDNA levels rise—before any symptoms or scans show progression—are randomly assigned t…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Triple threat: new drug combo aims to tackle Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis phase II pilot trial is testing a three-drug combination—radium-223, darolutamide, and standard hormone therapy—in men with high-volume metastatic hormone-sensitive prostate cancer. The goal is to see if adding radium-223 as maintenance therapy after initial treatment can im…
Phase 2 • Sponsor: Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Gut bacteria transplant may supercharge liver cancer immunotherapy
Disease control Not yet recruitingThis trial investigates whether transplanting healthy gut bacteria (fecal microbiota transplantation) can help immunotherapy work better in people with advanced liver cancer. Participants receive either a real transplant via colonoscopy or a sham procedure, alongside standard imm…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could a common Weight-Loss drug help hormone therapy work better for young women with endometrial cancer?
Disease control Not yet recruitingThis trial tests whether adding orlistat, a weight-loss drug that blocks fat absorption, to standard progestin therapy can improve treatment response in young women (45 or younger) with early-stage endometrial cancer or atypical endometrial hyperplasia who have low progesterone r…
Phase 2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Immunotherapy may treat skin cancer in kidney transplant patients without rejection
Disease control Not yet recruitingThis trial investigates whether the immunotherapy drug cemiplimab can shrink advanced cutaneous squamous cell carcinoma in people who have received a kidney transplant. Because immunotherapy can trigger organ rejection, participants also receive the steroid prednisone to protect …
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Heating the body to fight pancreatic cancer: a new trial tests Whole-Body hyperthermia
Disease control Not yet recruitingThis trial investigates whether raising the body's core temperature to 41.5°C for 4 hours, called whole-body hyperthermia, can improve outcomes when added to standard chemotherapy for people with metastatic pancreatic cancer that has progressed after initial treatment. The study …
Phase 2/3 • Sponsor: ElmediX • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug combo aims to stall advanced prostate cancer
Disease control Not yet recruitingThis study tests whether adding the experimental drug saruparib to standard hormone therapy can slow the growth of metastatic hormone-sensitive prostate cancer. It includes men whose cancer has not progressed after prior chemotherapy or a specific type of radiation therapy. Parti…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Smart cancer therapy: tailoring lung cancer treatment with a simple blood test
Disease control Not yet recruitingThis trial investigates a personalized approach for people with advanced EGFR-mutant non-small cell lung cancer who have not had prior treatment. Participants first take the targeted pill befotertinib for three weeks, then a blood test checks for minimal residual disease (MRD). T…
Phase 2 • Sponsor: Guangzhou University of Traditional Chinese Medicine • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Fewer radiation sessions may be just as effective for thymic tumors after surgery
Disease control Not yet recruitingThis clinical trial is testing a shorter, more intense course of radiation therapy (called hypofractionated radiotherapy) for people who have had surgery for thymic epithelial tumors, including thymoma and thymic carcinoma. The goal is to see if this approach can keep the tumor f…
Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Alcohol injection into adrenal tumors may offer surgery-free blood pressure control
Disease control Not yet recruitingThis study tests a procedure that uses a thin needle guided by an endoscope to inject alcohol into a benign adrenal tumor that produces too much aldosterone, a hormone that raises blood pressure. The goal is to destroy the tumor without surgery. The trial enrolls 30 adults with l…
Sponsor: Chongqing Medical University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug cocktail aims to outsmart untreatable bile duct cancer
Disease control Not yet recruitingThis clinical trial tests a new approach for people with a type of bile duct cancer that cannot be removed by surgery. It compares a combination of targeted therapy and a procedure that delivers chemotherapy directly to the liver against standard chemotherapy. The goal is to see …
Phase 3 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Virtual cooking classes aim to boost health for hispanic prostate cancer survivors and their families
Disease control Not yet recruitingThis study tests whether a 12-week virtual cooking and nutrition program is practical and helpful for Hispanic prostate cancer survivors and their caregivers. Participants attend nutrition education, cooking classes, and health coaching sessions online. The goal is to see if the …
Sponsor: University of Arizona • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New Dual-Action antibody could extend lives in stomach cancer
Disease control Not yet recruitingThis phase 3 trial tests whether adding an experimental drug called cadonilimab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. Cadonilimab is a bispecific antibody that targets two immune checkpoints (PD-1 and CTLA-4) …
Phase 3 • Sponsor: Akeso • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could adding chemo to tarlatamab overcome resistance in lung cancer?
Disease control Not yet recruitingThis phase 2 trial is testing whether giving platinum-based chemotherapy (carboplatin and etoposide) together with the immunotherapy tarlatamab can help patients with advanced small-cell lung cancer whose disease has worsened while on tarlatamab alone. The study enrolls about 54 …
Phase 2 • Sponsor: University of Cologne • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Chemotherapy drug temozolomide under review for tough pituitary tumors
Disease control Not yet recruitingThis study looks at how well the chemotherapy drug temozolomide works for people with aggressive pituitary tumors or pituitary cancer that hasn't responded to standard treatments like surgery or radiation. Researchers are collecting data from medical records across multiple hospi…
Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New skin patch could speed recovery after skin cancer removal
Disease control Not yet recruitingThis trial tests whether a new skin graft substitute (CAMP) plus standard wound care helps wounds heal faster after Mohs surgery for skin cancer compared to standard care alone. About 160 adults who have had Mohs surgery for a skin cancer will be randomly assigned to receive eith…
Phase 4 • Sponsor: BioLab Holdings • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Triple-Drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a combination of three drugs—tislelizumab, bevacizumab, and capecitabine—in people with advanced solid tumors. The trial focuses on two challenging groups: those whose cancers have stopped responding to immunotherapy and those with tumors that have spread to the …
Phase 1/2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Radiation may spare early rectal cancer patients from radical surgery
Disease control Not yet recruitingThis observational study follows about 196 adults with early-stage (pT1) rectal cancer who have high-risk features after local tumor removal. Instead of undergoing radical surgery that often requires a colostomy, participants receive adjuvant radiotherapy or chemoradiotherapy. Th…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat stomach cancers
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan (Sac-TMT) and fruquintinib—as a second-line treatment for people with advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after initial therapy. The study enrolls about 45 par…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New pill targets cancer growth at the genetic level
Disease control Not yet recruitingThis trial tests an experimental drug called SYH2095, taken as a daily pill, in people with advanced solid tumors that have no effective standard treatment. The drug blocks a protein (KAT6A/B) involved in cancer cell growth. The study aims to find a safe dose and check for early …
Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New drug combo aims to outsmart lung cancer that resists immunotherapy
Disease control Not yet recruitingThis trial tests a combination of two drugs—tislelizumab and SYS6010—in people with advanced non-small cell lung cancer (NSCLC) whose cancer has progressed after immunotherapy. Tislelizumab is an approved immunotherapy, and SYS6010 is an experimental drug that targets EGFR on can…
Phase 1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Simple blood tests could spot liver cancer earlier in diabetics
Disease control Not yet recruitingThis study investigates whether regular blood tests can detect liver cancer earlier in people with type 2 diabetes who also have significant liver scarring. Participants are randomly assigned to either a surveillance group receiving specialized blood tests every six months or a s…
Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a diabetes drug slow breast cancer growth?
Disease control Not yet recruitingThis phase 2 trial investigates whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in people with early-stage hormone-receptor-positive breast cancer. Participants receive tirzepatide alone, the standard hormone therapy letrozole alone, or both t…
Phase 2 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Custom-Made vaccine aims to boost immune attack on kidney tumors
Disease control Not yet recruitingThis early-stage trial tests whether a personalized vaccine, made from each patient's unique tumor mutations, can safely boost the effects of the immunotherapy drug pembrolizumab in people with advanced kidney cancer. The vaccine is designed to train the immune system to recogniz…
Phase 1 • Sponsor: Jian Lin • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could removing the primary tumor boost survival in stage IV breast cancer with Bone-Only spread?
Disease control Not yet recruitingThis trial investigates whether surgically removing the primary breast tumor, followed by standard systemic therapy, improves survival compared to systemic therapy alone in women with stage IV breast cancer that has spread only to a single bone site. The study enrolls women aged …
Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug TAX2 targets Hard-to-Treat cancers in first human trial
Disease control Not yet recruitingThis study tests an experimental drug, TAX2, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in more people. Researchers will monitor side effects, h…
Phase 1/2 • Sponsor: Apmonia Therapeutics • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New targeted pill holds promise for rare salivary gland cancer that spreads
Disease control Not yet recruitingThis phase 2 trial tests the drug zanzalintinib in people whose adenoid cystic carcinoma (a rare salivary gland cancer) has returned or spread. Despite initial surgery and radiation, about half of patients experience recurrence, and current treatments offer limited benefit. Parti…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Pre-Surgery cocktail aims to boost liver cancer outcomes
Disease control Not yet recruitingThis study tests whether giving a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted drug (rivoceranib) before surgery can improve outcomes for people with liver cancer that can be surgically removed. Participants receive the drug combination first, then und…
Phase 2 • Sponsor: Affiliated Hospital of Guangdong Medical University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Could a stronger first dose of targeted radiation beat back advanced prostate cancer?
Disease control Not yet recruitingThis phase 1 trial tests whether giving a higher first dose of the radioactive drug Lu-177-PSMA-617 can improve treatment for men with metastatic castration-resistant prostate cancer. The drug targets a protein on prostate cancer cells and delivers radiation to kill them. Researc…
Phase 1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail aims to tackle Hard-to-Treat stomach cancer
Disease control Not yet recruitingThis study tests a new biologic drug called HCB101 in combination with other cancer drugs (zolbetuximab and chemotherapy) for people with advanced gastric or gastro-esophageal cancer. The goal is to find a safe dose and see if the combination can shrink tumors. About 40 adults wi…
Phase 1/2 • Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Two-Drug combo aims to shrink vulvar tumors before surgery
Disease control Not yet recruitingThis trial tests whether combining an immune-boosting cream (imiquimod) with a low dose of an immunotherapy drug (nivolumab) can shrink vulvar squamous cell carcinoma tumors before surgery. About 50 women with resectable, early-to-moderate stage vulvar cancer will receive the dru…
Phase 1/2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could an asthma drug help fight lung cancer? early trial investigates
Disease control Not yet recruitingThis pilot study tests whether an inhaled drug called cromolyn sodium, already used for asthma, is safe and feasible for people with locally advanced lung cancer. The drug works by calming mast cells, which may play a role in tumor growth and treatment resistance. About 5 to 10 p…
Phase 1 • Sponsor: Carcinex Inc • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo aims to boost surgery success in colon cancer
Disease control Not yet recruitingThis phase 2 trial is testing whether giving two drugs—Zanzalintinib and Retifanlimab—before surgery can help patients with early-stage colon cancer. The study enrolls adults aged 18 to 80 with a type of colon cancer called pMMR that can be removed surgically. Participants receiv…
Phase 2 • Sponsor: Northwell Health • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Radiotherapy revolution: could 5 sessions replace 25 for endometrial cancer?
Disease control Not yet recruitingThis trial explores whether a new type of radiotherapy called CT online-adaptive radiotherapy can safely deliver treatment for endometrial cancer in just 5 sessions over a week and a half, instead of the usual 25 sessions over 5 weeks. The study includes 30 adults who have had su…
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Freezing breast tumors: a new hope for metastatic cancer control?
Disease control Not yet recruitingThis study investigates cryoablation, a procedure that freezes and destroys tumor tissue, for treating the primary breast tumor in women with metastatic breast cancer. The goal is to see if this minimally invasive approach can control the local tumor for 12 months while patients …
Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Short-Course radiation may boost immunotherapy and chemo for stomach cancer
Disease control Not yet recruitingThis study investigates whether adding a short course of radiotherapy before surgery, alongside a PD-1 inhibitor (serplulimab) and chemotherapy (SOX), can improve outcomes for people with locally advanced upper stomach or gastroesophageal junction cancer. Participants are randoml…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New bladder cancer drug aims to fight tumors without harming nerves
Disease control Not yet recruitingThis phase II trial compares a new targeted drug, sacituzumab tirumotecan (Sac-TMT), to other antibody-drug conjugates (ADCs) in people with advanced urothelial carcinoma (bladder cancer) that has worsened after prior treatment. The main goal is to see if Sac-TMT causes less seve…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New PET tracer aims to light up hidden cancer targets
Diagnosis Not yet recruitingResearchers are testing a new PET/CT imaging tracer called [68Ga]-LY4257529 that targets a protein called GRPR, which some cancers make in large amounts. The study includes up to 60 adults with breast cancer or other tumors known or suspected to express GRPR, such as prostate, ov…
Early phase 1 • Sponsor: Jewish General Hospital • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Mapping the DNA test that decides who gets PARP inhibitors
Diagnosis Not yet recruitingResearchers are reviewing medical records from about 1,125 women in Italy with newly diagnosed advanced high-grade epithelial ovarian cancer. The study focuses on how hospitals test tumors for homologous recombination deficiency (HRD), a DNA repair flaw that can make PARP inhibit…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can a glowing dye show surgeons where head and neck tumors end?
Diagnosis Not yet recruitingResearchers at Washington University School of Medicine are studying whether a fluorescent dye called indocyanine green can help visualize the edges of head and neck squamous cell carcinoma during surgery. The study plans to enroll 25 adults who are having surgery for confirmed o…
Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
AI boosts colonoscopy accuracy in massive new trial
Diagnosis Not yet recruitingThis study tests whether an artificial intelligence (AI) system can help doctors spot more precancerous polyps and colorectal cancers during colonoscopy compared to standard procedures. Over 3,300 adults scheduled for screening or surveillance will be randomly assigned to AI-assi…
Sponsor: Zhejiang University • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Blood test maps hidden resistance signal in advanced breast cancer
Diagnosis Not yet recruitingPeople with hormone receptor-positive, HER2-negative advanced breast cancer often start treatment with a CDK4/6 inhibitor plus an aromatase inhibitor. Over time, some tumors develop an ESR1 mutation that can make the aromatase inhibitor stop working. This study takes blood sample…
Sponsor: Institut fuer Frauengesundheit • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Radioactive antibody aims to light up hidden solid tumors
Diagnosis Not yet recruitingResearchers are testing a new imaging agent called 111In-TJD-31 that targets placental alkaline phosphatase (ALPP), a protein found on many solid tumor cells but rarely in healthy adult tissue. The study enrolls 8 participants: 2 healthy volunteers who give blood samples and 6 pa…
Phase 1 • Sponsor: Yong He • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Glow-in-the-dark dye may help surgeons spot hidden prostate cancer cells
Diagnosis Not yet recruitingThis trial tests whether a fluorescent dye called zopocianine can make prostate cancer cells glow under near-infrared light during surgery. Men with prostate cancer scheduled for prostatectomy receive a single dose of the dye before surgery. The goal is to see if the dye helps su…
Phase 2/3 • Sponsor: Clinton Bahler • Aim: Diagnosis
Last updated Sep 12, 2026 00:00 UTC
-
Can a simple blood test spot pancreatic cancer early enough to save lives?
Diagnosis Not yet recruitingThis registry study follows 400 people at increased risk for pancreatic ductal adenocarcinoma who receive PancreaSure, a blood test designed to detect early-stage disease. Researchers track whether the test results lead doctors to change surveillance plans, such as scheduling mor…
Sponsor: Immunovia, Inc. • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
Can a glowing dye reveal hidden bladder cancer during surgery?
Diagnosis Not yet recruitingThis trial tests whether a fluorescent dye called TTP-ICG, which targets a protein found on bladder cancer cells, can help surgeons spot tumors during surgery. People with suspected or confirmed non-muscle invasive bladder cancer will have the dye placed into their bladder before…
Phase 1/2 • Sponsor: Yunnan Cancer Hospital • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
MRI scans may reveal which throat cancer patients need stronger treatment
Diagnosis Not yet recruitingThis study tests whether special MRI scans can predict how well HPV-positive throat cancer responds to standard chemotherapy and radiation. Researchers will scan 30 adults before treatment and track their outcomes. The goal is to see if MRI patterns can identify low-risk patients…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
New camera modes could sharpen Colonoscopy's eye for precancerous polyps
Diagnosis Not yet recruitingThis trial tests two new imaging modes, VIST and SFI, during colonoscopy to see if they help doctors find and classify colorectal polyps better than standard white light. About 990 adults undergoing screening or surveillance colonoscopy will be randomly assigned to one of the thr…
Sponsor: Alexandre Vontobel Padoin • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
AI takes on the microscope: a new test for skin cancer diagnosis
Diagnosis Not yet recruitingThis study asks whether an artificial intelligence algorithm can accurately identify basal cell carcinoma, a common type of skin cancer, from digitized tissue samples. Researchers will compare the AI's diagnostic performance—its sensitivity and specificity—against the assessments…
Sponsor: Al-Azhar University • Aim: Diagnosis
Last updated Aug 28, 2026 00:00 UTC
-
Can a standardized MRI accurately stage esophageal cancer?
Diagnosis Not yet recruitingThis trial aims to develop and validate a standardized MRI protocol for staging esophageal squamous cell carcinoma and assessing how well tumors respond to neoadjuvant therapy. About 500 adults scheduled for surgery will be enrolled, with some undergoing MRI before surgery and ot…
Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Diagnosis
Last updated Aug 20, 2026 00:00 UTC
-
A sharper eye on prostate cancer return: PSMA PET vs. MRI
Diagnosis Not yet recruitingThis pilot study investigates whether a PSMA PET scan, using an injected radiotracer, can detect clinically significant prostate cancer recurrence one year after focal HIFU treatment, compared with the standard MRI. About 30 men with prostate cancer who meet specific criteria wil…
Phase 4 • Sponsor: University Hospital, Toulouse • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
A sharper eye on prostate cancer: could new imaging spare healthy tissue?
Diagnosis Not yet recruitingThis pilot study is testing whether a special PET/MRI scan using a radioactive tracer called 68Ga-PSMA-11 can better identify all areas of significant prostate cancer in men with localized disease. The goal is to improve selection for focal therapy, a treatment that targets only …
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Aug 07, 2026 00:00 UTC
-
AI eye on polyps: could a computer match the microscope?
Diagnosis Not yet recruitingThis trial tests whether an AI system called GI Genius can help doctors accurately tell apart small colorectal polyps (5 mm or less) during a colonoscopy—identifying which ones are harmless versus those that need monitoring. For each small polyp, doctors first record their own di…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
Can a simple MRI and blood test catch pancreatic cancer earlier?
Diagnosis Not yet recruitingThis pilot study tests whether a structured case-finding pathway can help detect pancreatic cancer earlier in Swiss primary care. Adults aged 60 or older with warning signs like new-onset diabetes, unexplained weight loss, or a family history of pancreatic cancer are invited to u…
Sponsor: Saskia Hendrich • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
Dye-Free laser imaging could replace standard dye in colorectal surgery
Diagnosis Not yet recruitingThis study compares two imaging methods for checking blood flow to the bowel during colorectal surgery: the standard technique using a dye called indocyanine green (ICG) and a newer dye-free method called Laser Speckle Contrast Imaging (LSCI). About 30 adults having elective colo…
Sponsor: Leiden University Medical Center • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC
-
New ultrasound technique could reveal hidden blood vessels in liver tumors
Diagnosis Not yet recruitingThis study tests a new ultrasound method called super-resolution ultrasound (SRUS) to see tiny blood vessels in liver tumors. Current scans show only larger vessels, but SRUS can detect vessels as small as 20 micrometers. Researchers will compare blood flow patterns in different …
Sponsor: Eastern Hepatobiliary Surgery Hospital • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
Scientists hunt for biomarkers to catch pancreatic cancer before it strikes
Diagnosis Not yet recruitingThis study aims to find molecular clues that could predict whether certain pancreatic growths will turn into cancer. Researchers will analyze tissue from patients having pancreatic surgery, using advanced genetic and protein tests on both the original tissue and lab-grown 3D cell…
Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Diagnosis
Last updated Jul 18, 2026 00:00 UTC
-
New imaging tracer could spot hidden cancers and fibrosis in one scan
Diagnosis Not yet recruitingThis study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …
Phase 1/2 • Sponsor: Martin Huellner • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Breath of discovery: simple test may sniff out lung cancer
Diagnosis Not yet recruitingThis pilot study explores whether a breath sample collected with the VosCryo device can provide enough cellular material to help diagnose advanced lung cancer. Researchers will compare breath samples from 12 people with late-stage lung cancer and 12 healthy relatives to see if th…
Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
New blood tests aim to catch ovarian cancer earlier
Diagnosis Not yet recruitingThis study evaluates several experimental blood tests designed to detect ovarian cancer earlier. Researchers compare results from people with ovarian cancer to those without cancer to see how well the tests distinguish between the two. The tests look for specific changes in the b…
Sponsor: National and Kapodistrian University of Athens • Aim: Diagnosis
Last updated Jul 11, 2026 00:00 UTC
-
Spinal fluid DNA test could personalize brain cancer therapy
Diagnosis Not yet recruitingThis study explores whether analyzing tumor DNA in cerebrospinal fluid can help doctors make better treatment decisions for people with malignant brain tumors or brain metastases from lung or breast cancer. Participants undergo a standard spinal tap or fluid collection, and the f…
Sponsor: Alireza Mansouri • Aim: Diagnosis
Last updated Jul 10, 2026 00:00 UTC
-
Can a new drug wipe out hidden cancer DNA and stop colorectal cancer from returning?
Prevention Not yet recruitingResearchers are testing an experimental drug called INCA33890 in people with stage II or III colorectal cancer who have finished surgery and chemotherapy but still have tiny amounts of tumor DNA in their blood. This leftover DNA, called circulating tumor DNA or ctDNA, can signal …
Phase 2 • Sponsor: Incyte Corporation • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Could a nasal tube replace a temporary ileostomy after rectal cancer surgery?
Prevention Not yet recruitingResearchers are testing whether a nasal catheter that diverts stool from the small intestine can prevent leaks after surgery for mid to low rectal cancer. The trial compares this catheter approach with a standard protective ileostomy, a temporary opening in the abdomen to divert …
Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
Can heated saline during bladder surgery stop tumors from coming back?
Prevention Not yet recruitingResearchers are testing whether heated saline can be safely given during surgery to remove early bladder tumors. The study enrolls adults with small papillary tumors that have not grown into the bladder muscle. Participants receive either heated saline or room-temperature saline …
Sponsor: CAMC Health System • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
Neighbors may hold the key to boosting colon cancer screening
Prevention Not yet recruitingThis trial tests a program where trained community members, called Colon Health Champions, lead discussions about colorectal cancer risk and screening barriers. The goal is to see if this peer-led approach is feasible and acceptable for adults aged 45 to 75 who are due for routin…
Sponsor: Virginia Commonwealth University • Aim: Prevention
Last updated Sep 03, 2026 00:00 UTC
-
Can a phone app help pancreatic cancer patients eat better during treatment?
Symptom relief Not yet recruitingResearchers are testing whether a digital nutrition app called STRONG, paired with remote dietitian counseling, is practical and helpful for adults with pancreatic ductal adenocarcinoma who are starting chemotherapy or radiation. About 80 participants join the study and are assig…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a new drug shield kidneys from chemotherapy damage?
Symptom relief Not yet recruitingResearchers are testing an experimental drug called GMDTC in adults with solid tumors who have mild kidney problems caused by cisplatin chemotherapy. The trial aims to find out if GMDTC is safe, what side effects it causes, and how the body processes it. Participants receive cisp…
Phase 1 • Sponsor: Guangdong Jianersheng Pharmaceutical Technology Co., Ltd. • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a Dietitian's plan help older pancreatic cancer patients feel better?
Symptom relief Not yet recruitingResearchers are testing whether personalised nutritional care from a trained dietitian improves quality of life for people aged 65 and older with pancreatic ductal adenocarcinoma. About 250 participants will be randomly assigned to either six months of individualised nutrition su…
Sponsor: Inna Chen, MD • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Shorter radiation course tested for advanced head and neck cancer
Symptom relief Not yet recruitingResearchers compare two palliative radiation schedules for people with incurable head and neck cancer. The standard Split Course takes several weeks and often causes hard-to-tolerate side effects. The study tests whether a shorter Quad Shot regimen can shrink tumors and ease symp…
Sponsor: Instituto Nacional de Cancerologia, Columbia • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can exercise and nutrition prehab help breast cancer patients through chemo?
Symptom relief Not yet recruitingResearchers at City of Hope test whether a prehabilitation program is practical for breast cancer patients receiving chemotherapy before surgery. The program includes aerobic exercise, nutrition guidance, and education, all led by a physiatry team. Twenty participants will be ask…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Can dancing ease the exhaustion of breast cancer treatment?
Symptom relief Not yet recruitingResearchers are testing whether a 12-week supervised dance-based exercise program can reduce cancer-related fatigue in women with newly diagnosed breast cancer who are having treatment before surgery. The study includes 104 women aged 18 to 60 who will be randomly assigned to eit…
Sponsor: Comenius University • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Donor nerve grafts put to the test for restoring feeling after mastectomy
Symptom relief Not yet recruitingThis trial tests whether adding a donor nerve graft during implant-based breast reconstruction helps women regain breast and nipple sensation after nipple-sparing mastectomy. Each participant has one breast randomly chosen to receive the graft, while the other breast serves as a …
Phase 4 • Sponsor: Endeavor Health • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Can a spinal pump deliver better pain relief for pancreatic cancer?
Symptom relief Not yet recruitingThis pilot study tests whether delivering pain medication directly to the spinal cord via an implanted pump can better control severe pain in people with pancreatic cancer. The trial enrolls adults whose pain is not well managed by standard treatments or who cannot take typical p…
Sponsor: Clinique Bizet • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Scalp cancer surgery that leaves hair follicles behind
Symptom relief Not yet recruitingResearchers are testing a modified surgical technique for squamous cell carcinoma in situ on the scalp, an early form of skin cancer. Standard surgery can remove deep tissue that holds hair follicles, causing permanent bald spots. This pilot study uses partial thickness excision,…
Sponsor: The Cooper Health System • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can a drug stop muscle loss in lung cancer? new trial aims to find out
Symptom relief Not yet recruitingThis early-stage trial tests whether the drug ponsegromab can help adults with advanced non-small cell lung cancer who are losing muscle mass (cachexia). About 80 participants will receive either ponsegromab or a placebo. The study measures changes in muscle size and physical fun…
Phase 1 • Sponsor: Pfizer • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
A group therapy approach may ease sexual distress after GI cancer
Symptom relief Not yet recruitingThis trial tests a virtual mind-body group program for female survivors of colorectal and anal cancer who experience sexual well-being challenges. Participants join weekly group sessions with other survivors to learn coping skills for physical changes, social factors, and thought…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
AI chatbot may calm nerves after a prostate cancer diagnosis
Symptom relief Not yet recruitingThis trial tests whether an AI-powered support tool, accessed through a WeChat Mini Program, can reduce anxiety in men recently diagnosed with metastatic prostate cancer. Participants are randomly assigned to use the platform with the AI agent or without it for the first two week…
Sponsor: Fudan University • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Talking about sex after cancer: telehealth therapy may improve recovery
Symptom relief Not yet recruitingThis study tests whether adding telehealth sex therapy to standard pelvic floor physical therapy helps men recover urinary and sexual function after prostate cancer treatment. All participants receive pelvic floor therapy and education on using a vacuum erection device. Half are …
Sponsor: Duke University • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Can a psychedelic ease the existential weight of advanced cancer?
Symptom relief Not yet recruitingThis pilot trial tests whether psilocybin-assisted therapy can help adults with advanced cancer who feel demoralized, hopeless, or distressed about their illness. Participants receive a single dose of psilocybin (either 25 mg or 5 mg) during a group session, paired with either mi…
Phase 2 • Sponsor: University of Calgary • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Talking through memories may lighten the load for dementia caregivers
Symptom relief Not yet recruitingThis study tests a program called Dyadic Life Review, where older adults with advanced cancer and memory problems talk through their life stories with a caregiver. The goal is to see if these conversations reduce caregiver burden and stress while bringing the pair closer together…
Sponsor: University of Rochester • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Music and lidocaine timing: a simple recipe for a gentler cystoscopy?
Symptom relief Not yet recruitingThis trial tests whether listening to music or letting numbing medication sit longer can reduce pain during cystoscopy, a procedure that examines the bladder. About 1,740 people undergoing cystoscopy for bladder cancer diagnosis or surveillance will be randomly assigned to differ…
Phase 3 • Sponsor: Florian Schroeck • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
AI assistant aims to ease thyroid cancer anxiety before surgery
Symptom relief Not yet recruitingThis study tests whether an online educational tool called THRIVE, powered by artificial intelligence, can help people newly diagnosed with thyroid cancer feel less anxious and more confident about their treatment choices. Participants use the tool on their own device before meet…
Sponsor: Cedars-Sinai Medical Center • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Magnetic pulses to the brain may help cancer patients sleep better
Symptom relief Not yet recruitingThis trial tests whether low-frequency repetitive transcranial magnetic stimulation (rTMS) can improve sleep quality in adults with advanced non-small cell lung cancer who have trouble sleeping during hospital stays. Researchers will randomly assign 160 participants to receive ei…
Phase 2 • Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Estrogen patch may ease hot flashes in prostate cancer treatment
Symptom relief Not yet recruitingThis study tests whether adding estrogen to standard prostate cancer treatment can improve quality of life for 60 men with metastatic hormone-sensitive prostate cancer. Standard therapy often causes hot flashes and other side effects by lowering estrogen. The study compares estro…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Can a home care plan ease bladder cancer treatment side effects?
Symptom relief Not yet recruitingThis trial tests a personalized home-based supportive care program for people with non-muscle-invasive bladder cancer who receive intravesical perfusion therapy after surgery. The program provides physical symptom relief, psychological support, and education to help patients mana…
Sponsor: Nanjing First Hospital, Nanjing Medical University • Aim: Symptom relief
Last updated Aug 26, 2026 00:00 UTC
-
Could a single radiation dose ease bone pain as well as five?
Symptom relief Not yet recruitingThis trial is testing whether a single, higher dose of radiation (8 Gy) can relieve pain from bone metastases as effectively as a standard course of five smaller doses (20 Gy total). The study includes adults with cancer that has spread to the bones and who have significant pain.…
Sponsor: Oman Ministry of Health • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Virtual therapy may ease breast cancer treatment side effects
Symptom relief Not yet recruitingThis study tests a 6-session telehealth program called STRIDE, which uses cognitive behavioral therapy to help women with hormone-positive breast cancer manage side effects from adjuvant endocrine therapy. Participants will be randomly assigned to either the STRIDE program or usu…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Can a simple text message transform cancer care?
Symptom relief Not yet recruitingThis trial tests whether regular text-message check-ins can help advanced cancer patients get palliative care support earlier. Patients receive a text every two weeks asking them to rate their symptoms online. If any symptoms are concerning, a coordinator calls to assess and mana…
Sponsor: National Cancer Centre, Singapore • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Gut bacteria may shield nerves from chemo damage – a trial puts it to the test
Symptom relief Not yet recruitingThis phase III trial tests whether a daily probiotic supplement, OXXYSLAB®, can reduce peripheral neuropathy—nerve damage causing pain and numbness—in people with stage III colon cancer receiving oxaliplatin-based chemotherapy (FOLFOX or XELOX). About 130 participants will take e…
Sponsor: Centre Francois Baclesse • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
A personalized approach to breathlessness: could a stepped-care program offer relief for lung cancer patients?
Symptom relief Not yet recruitingShortness of breath, or dyspnea, affects most lung cancer patients and often persists despite standard treatments. This pilot study tests a stepped-care behavioral intervention called INSPIRE, which starts with brief coping skills and adds more intensive psychological support onl…
Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
New program aims to give veterans with advanced cancer a stronger voice in their End-of-Life care
Symptom relief Not yet recruitingThis study tests a program that pairs veterans with advanced cancer with a lay health worker who helps them discuss their goals and preferences for care with their doctors. The goal is to increase the number of veterans who have these important conversations and document their wi…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Gentle belly massage may speed gut recovery after colon cancer surgery
Symptom relief Not yet recruitingThis trial investigates whether gentle abdominal massage, performed early after colon cancer surgery, can help the intestines start working again more quickly. Many patients experience a temporary slowdown in gut function (postoperative ileus) that causes bloating, pain, and naus…
Sponsor: University Hospital, Grenoble • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Zapping nerves with radiation may ease pancreatic cancer pain
Symptom relief Not yet recruitingThis trial tests whether a short course of precisely targeted radiotherapy can safely reduce severe pain in people with advanced pancreatic cancer. The radiation is aimed at the coeliac plexus, a network of nerves in the abdomen that often causes pain when affected by the tumor. …
Phase 2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
New radiation technique aims to shield airways and preserve lung function
Symptom relief Not yet recruitingThis trial compares standard radiation therapy with a new method that specifically avoids damaging small airways in the lungs. The goal is to see if this airway-sparing approach helps patients with stage III non-small cell lung cancer retain better breathing function after treatm…
Phase 2 • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Can Real-World data match trial results for pembrolizumab in Triple-Negative breast cancer?
Knowledge-focused Not yet recruitingResearchers in Korea are reviewing medical records from about 2,000 patients with triple-negative breast cancer who received pembrolizumab plus chemotherapy before surgery. The study measures how many patients had no detectable cancer left in their breast and lymph nodes at surge…
Sponsor: Yeon Hee Park • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Could you help scientists unlock genetic cancer secrets?
Knowledge-focused Not yet recruitingThis study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can Real-World data reveal the best rectal cancer treatment?
Knowledge-focused Not yet recruitingThis observational study gathers information from routine care on how localized rectal cancer is treated across Austrian hospitals. It aims to document the variety of treatment approaches, including total neoadjuvant therapy and immunotherapy, and their outcomes. By analyzing thi…
Sponsor: Austrian Breast & Colorectal Cancer Study Group • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
New study aims to slash cervical cancer deaths in HIV-positive women
Knowledge-focused Not yet recruitingThis study tests better ways to screen and treat cervical cancer in women living with HIV in Kenya, who face a much higher risk. Researchers will use HPV self-testing, care navigators, and a mobile app to help more women get diagnosed and treated. The goal is to find strategies t…
Sponsor: Emory University • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Mapping how thyroid tumors spread and what surgery leaves behind
Knowledge-focused Not yet recruitingResearchers at Sohag University Hospitals are reviewing the medical records of 30 people treated for papillary thyroid cancer, the most common type of thyroid cancer. The study examines how far tumors extended beyond the thyroid gland and which complications appeared soon after s…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Canadian study aims to unlock secrets of cancer immunotherapy
Knowledge-focused Not yet recruitingThis study collects tumor tissue and blood samples from 120 cancer patients who are receiving or will receive immunotherapy. The samples will be stored in a biobank for future research to better understand how these treatments work. No direct treatment is given; the goal is to ga…
Sponsor: Canadian Cancer Trials Group • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can a video keep thyroid cancer patients on track after surgery?
Knowledge-focused Not yet recruitingAfter thyroid surgery for differentiated thyroid cancer, patients often need to take thyroid hormone at doses that keep TSH in a specific target range. Researchers at West China Hospital are testing whether adding a short educational video to standard instructions helps patients …
Sponsor: West China Hospital • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Finger-Prick blood tests could let lung cancer patients skip clinic visits
Knowledge-focused Not yet recruitingResearchers are testing whether people with non-small cell lung cancer can collect their own small blood samples at home using a finger-prick kit. Participants receive standard treatment with docetaxel, paclitaxel, alectinib, or lorlatinib, and the samples measure how much cancer…
Sponsor: Karolinska Institutet • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Why does esophageal cancer come back after treatment? researchers search medical records for clues
Knowledge-focused Not yet recruitingResearchers are reviewing medical records of 100 people with esophageal squamous cell carcinoma who received immunotherapy plus chemotherapy before surgery to remove the cancer. The study examines when and where cancer returns and which patient traits, treatment details, scan res…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Leftover immunotherapy may boost chemo: new study investigates timing
Knowledge-focused Not yet recruitingThis study looks at how much pembrolizumab (an immunotherapy drug) remains in the blood after treatment ends and whether that affects how well chemotherapy works later. Researchers will follow 110 people with non-small cell lung cancer or head and neck cancer who have stopped pem…
Phase 4 • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Robot surgery showdown: single port vs multi port for cancer
Knowledge-focused Not yet recruitingThis study will compare two types of robot-assisted surgery for prostate or kidney cancer: single-port (one small incision) and multi-port (several incisions). Researchers will track 376 adults to see which approach leads to a shorter hospital stay and better recovery. The study …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Hidden bacteria in prostate tumors may shape how the immune system fights cancer
Knowledge-focused Not yet recruitingResearchers at Anhui Medical University are studying bacteria found inside prostate tumors and how they relate to the immune system. The study uses leftover tissue samples and archived slides from about 100 men with prostate cancer or benign prostate disease. Scientists will sequ…
Sponsor: Anhui Medical University • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Prostate tumors hide a Nerve-Fueled neighborhood, and scientists are mapping it
Knowledge-focused Not yet recruitingResearchers at Anhui Medical University are studying how prostate cancer invades nerves, a feature linked to aggressive tumors and recurrence after surgery. They plan to collect tissue and clinical data from about 120 prostate cancer patients and compare nerve-invaded areas, ordi…
Sponsor: Anhui Medical University • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Your gut bacteria may hold the key to whether immunotherapy works
Knowledge-focused Not yet recruitingResearchers are studying whether the mix of bacteria in a person's gut can predict how well they respond to immunotherapy drugs called immune checkpoint inhibitors. The trial enrolls about 360 adults with advanced non-small cell lung cancer, melanoma, endometrial cancer, or cervi…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Can Re-Assessing bile duct cancer treatment open the door to surgery?
Knowledge-focused Not yet recruitingResearchers at Karolinska University Hospital are following 900 people diagnosed with intrahepatic or perihilar cholangiocarcinoma, two types of bile duct cancer. The study tracks how tumors respond to treatment, how patients feel and function, and changes in biomarkers over time…
Sponsor: Karolinska University Hospital • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Can a 2-week drug boost scan accuracy for hidden prostate cancer?
Knowledge-focused Not yet recruitingThis study looks at whether taking bicalutamide for two weeks can make PSMA PET/CT scans better at finding small amounts of prostate cancer that standard scans might miss. It involves 20 men with recurrent prostate cancer and very low PSA levels. Participants are randomly assigne…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Can brain imaging unlock the secrets of opioid addiction?
Knowledge-focused Not yet recruitingResearchers at Yale University are using PET brain scans with a radioactive tracer called [11C]OMAR to measure CB1 receptor levels in people with opioid use disorder who are stabilized on buprenorphine, compared to healthy controls. The study aims to see if CB1 receptor availabil…
Phase 1 • Sponsor: Yale University • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Why does lung surgery leave some patients breathless? glasgow team probes the right heart
Knowledge-focused Not yet recruitingSome people who have keyhole lung cancer surgery develop lasting breathlessness and struggle with gentle exercise, even if their breathing was fine before. Researchers suspect the right side of the heart, which pumps blood to the lungs, may be weakened by the extra pressure it fa…
Sponsor: University of Glasgow • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Thyroid surgery under the microscope: what 3,000 real operations reveal
Knowledge-focused Not yet recruitingResearchers at a Moscow medical center are studying the quality and outcomes of thyroid surgery using real-world clinical data. The study follows patients who had thyroid operations for benign or malignant disease, tracking complications, cancer results, and long-term outcomes. B…
Sponsor: Pirogov Russian National Research Medical University • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Bacteria living in head and neck tumors: cause, consequence, or clue?
Knowledge-focused Not yet recruitingResearchers want to know whether the bacteria living in and around head and neck squamous cell carcinoma differ from those in healthy tissue. Adults scheduled for a standard throat examination because of suspected cancer give three extra samples during that procedure: tumor tissu…
Sponsor: Centre Hospitalier Sud Francilien • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Brain tumor or aneurysm first? study weighs the safer sequence
Knowledge-focused Not yet recruitingResearchers are observing patients in China who have both a tumor in the sellar region of the brain and an unruptured intracranial aneurysm. The study compares three approaches: removing the tumor before treating the aneurysm, treating the aneurysm before removing the tumor, or r…
Sponsor: Cheng sen • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
AI takes aim at pancreatic cancer: can it forecast chemotherapy outcomes?
Knowledge-focused Not yet recruitingThis observational study tests whether artificial intelligence can predict how well pancreatic cancer responds to chemotherapy and how the disease may progress. Researchers will analyze data from 700 patients, including endoscopic ultrasound images, CT/MRI scans, lab results, and…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Can tracking symptoms improve care for children with advanced cancer?
Knowledge-focused Not yet recruitingThis observational study aims to understand how symptoms like pain, fatigue, and nausea change over time in children with advanced cancer. Researchers will ask children aged 8 to 18 and their caregivers to complete surveys about symptoms and overall health. The goal is to identif…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Doctors watch and learn: new study tracks endoscopy for pancreatic disease diagnosis
Knowledge-focused Not yet recruitingThis study will watch how doctors use a special camera (endoscopic ultrasound) to diagnose suspected pancreatic or bile duct diseases in 2500 adults across Lombardy, Italy. The goal is to see how accurate the procedure is, how safe it is, and how quickly patients get a final diag…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Can frailty predict recovery after gastric cancer surgery?
Knowledge-focused Not yet recruitingThis study follows 328 adults aged 60 and older who are having surgery for gastric cancer. Researchers will measure frailty, nutrition, and muscle mass before surgery, then track complications, delirium, and recovery afterward. The goal is to see whether these factors, along with…
Sponsor: Kocaeli City Hospital • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Mapping Real-World care for stomach cancer in greece
Knowledge-focused Not yet recruitingThis observational study tracks how patients with stage II to IVB gastric or gastroesophageal junction cancer are actually treated in routine clinical practice across Greece. Researchers will collect data on patient characteristics, treatment choices, timing of therapies, and bio…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Can a single surgery technique improve life after stomach cancer in two countries?
Knowledge-focused Not yet recruitingThis study looks back at medical records from high-volume hospitals in Russia and China to compare how patients with stomach cancer or cancer at the junction of the stomach and esophagus fare after a specific surgery called proximal gastrectomy with double-tract reconstruction. R…
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Personalized liver cancer treatment: a quest for predictive biomarkers
Knowledge-focused Not yet recruitingThis observational study follows 400 people with intermediate to advanced or unresectable hepatocellular carcinoma (the most common type of liver cancer) who are receiving systemic therapies such as atezolizumab plus bevacizumab or nivolumab plus ipilimumab, sometimes combined wi…
Sponsor: Shanghai Zhongshan Hospital • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Could a simple MRI replace a PET scan for safer cancer radiation?
Knowledge-focused Not yet recruitingThis study will test whether a special MRI scan (CSE-MRI) can accurately measure active bone marrow in men with metastatic prostate cancer, compared to a standard PET scan using a radioactive tracer (FLT). Fifteen participants will receive both scans at the same time using a comb…
Early phase 1 • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Blood test may spot hidden stomach cancer recurrence risk
Knowledge-focused Not yet recruitingThis study enrolls adults with stomach or gastroesophageal junction cancer who had a strong response to chemotherapy before surgery, with no or very little cancer left in the removed tissue. Researchers will use a personalized blood test that tracks tumor DNA to see if it can ide…
Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Blood test may reveal how rare cancer responds to treatment
Knowledge-focused Not yet recruitingResearchers at Johns Hopkins are testing whether a blood test called Signatera can reliably detect tumor DNA in people with high-grade upper tract urothelial cancer, a rare cancer of the urinary tract. The study will collect blood samples before, during, and after treatment to se…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Can we decode pancreatic cancer's resistance to chemotherapy?
Knowledge-focused Not yet recruitingThis study enrolls 150 adults with suspected or confirmed pancreatic cancer who are scheduled for chemotherapy. Researchers will collect tumor samples via endoscopic ultrasound before and during treatment to analyze gene activity. They aim to understand how the cancer changes acr…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Mapping the tumor microenvironment to predict prostate cancer therapy outcomes
Knowledge-focused Not yet recruitingThis study investigates whether detailed molecular mapping of prostate tumors can predict how well men with metastatic hormone-sensitive prostate cancer respond to androgen deprivation therapy (ADT) combined with second-generation hormonal agents like abiraterone or enzalutamide.…
Phase 2 • Sponsor: Anhui Medical University • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
A deep dive into tumor markers could personalize lung cancer care
Knowledge-focused Not yet recruitingResearchers are collecting blood and tumor tissue samples from 30 adults with relapsed small-cell lung cancer who are receiving a standard DLL3 T cell engager therapy. The goal is to track changes in tumor markers over time and see if those changes relate to how well the treatmen…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
AI measures bowel cleanliness to boost polyp detection
Knowledge-focused Not yet recruitingResearchers at Fudan University are testing whether an artificial intelligence tool can score bowel preparation quality by measuring fecal coverage during colonoscopy. The study enrolls 560 adults aged 45 to 75 who have not had a colonoscopy in the past three years. The goal is t…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Bladder cancer surgery: what happens after the bladder is removed?
Knowledge-focused Not yet recruitingThis study looks at the well-being and medical care of people in Korea who had their bladder removed (radical cystectomy) for bladder cancer. Using nationwide insurance records, researchers will track complications, hospital stays, readmissions, and survival up to three years aft…
Sponsor: Janssen Korea, Ltd., Korea • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Lung cancer study seeks to map patient journeys
Knowledge-focused Not yet recruitingThis study reviews medical records of 250 people with advanced or metastatic non-small cell lung cancer that has a specific change in the EGFR gene. Researchers want to learn about patients' backgrounds, the treatments they receive, and how well those treatments work. The goal is…
Sponsor: Janssen-Cilag Farmaceutica Ltda. • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Could Self-Swabs make anal cancer screening easier for people with HIV?
Knowledge-focused Not yet recruitingThis trial tests whether people living with HIV can collect their own anal swabs for anal cancer screening, compared with swabs taken by a clinician. About 700 participants in Australia will provide both types of swabs, which will be checked for high-risk HPV and precancerous cel…
Sponsor: Kirby Institute • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
A phone call could unlock early cancer detection for High-Risk groups
Knowledge-focused Not yet recruitingThis study tests a remote education program to help people at higher risk for pancreatic cancer learn about genetic testing and a blood test that screens for multiple cancers. The program targets Black, Latino/a, and Medicaid-enrolled individuals in Massachusetts who may have had…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Can tumor markers guide future ovarian cancer treatments?
Knowledge-focused Not yet recruitingThis study examines tumor samples from 320 Latin American women with advanced ovarian, fallopian tube, or peritoneal cancer to describe the presence of certain markers (FRα, HER2, PD-L1, HRD, and BRCA). Researchers will collect medical history and test archived tumor tissue to se…
Sponsor: Latin American Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Which Pre-Surgery combo extends life in esophageal cancer? a virtual trial seeks answers
Knowledge-focused Not yet recruitingThis study compares two standard pre-surgery treatments for a common type of esophageal cancer: chemoradiotherapy (radiation plus chemo) versus immunochemotherapy (immunotherapy plus chemo). Using data from 400 patients' medical records, researchers will analyze which approach is…
Sponsor: Henan Cancer Hospital • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Can pancreatic Cancer's inflammatory footprint be stopped?
Knowledge-focused Not yet recruitingThis observational study looks at how pancreatic cancer changes immune cells in the blood. Researchers will compare blood samples from 50 people with newly diagnosed, untreated pancreatic cancer to 50 age-matched people with a non-cancerous pancreatic condition. They aim to ident…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Could a simple scan and blood test outsmart liver cancer?
Knowledge-focused Not yet recruitingThis study looks at whether a structured surveillance program using regular ultrasound and a blood test (alpha-fetoprotein) can detect liver cancer at an earlier, more treatable stage in people at high risk. About 300 adults with liver cirrhosis, chronic hepatitis B, or advanced …
Sponsor: D'Or Institute for Research and Education • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Which rectal cancer surgery preserves quality of life better? a study investigates
Knowledge-focused Not yet recruitingThis study looks at people who had surgery for advanced lower rectal cancer, comparing two procedures: one that removes the rectum and anus (requiring a permanent stoma) and one that removes the rectum but keeps the anus (with a reconnection). The goal is to see which approach le…
Sponsor: University Hospital, Grenoble • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
A new clue in the fight against colorectal cancer recurrence?
Knowledge-focused Not yet recruitingThis study looks at whether a combination of immune cell activity, genetic changes, and imaging features can help predict if colorectal cancer that has spread to the liver will come back after surgery. Researchers will analyze tumor tissue, blood samples, and scans from about 210…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Bone scan boost: could Whole-Body SPECT sharpen radiation targeting for metastatic prostate cancer?
Knowledge-focused Not yet recruitingThis trial explores whether a whole-body bone scan (SPECT/CT) taken in the treatment position can help doctors plan stereotactic radiotherapy more precisely for prostate cancer that has spread to the bones. Thirty patients will receive the scan in addition to standard imaging, an…
Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Artificial intelligence may predict ovarian cancer recurrence — a large study puts it to the test
Knowledge-focused Not yet recruitingThis study looks at whether artificial intelligence and detailed molecular analysis can help predict how high-grade serous ovarian cancer will behave after surgery. Researchers will analyze tumor images, genetic data, and patient records from 1,300 women to build a model that for…
Sponsor: The Affiliated Hospital of Qingdao University • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Blood clot marker may predict immunotherapy success in advanced skin cancer
Knowledge-focused Not yet recruitingThis study looks at whether a routine blood test measuring D-dimer levels can predict if the immunotherapy drug cemiplimab will control advanced cutaneous squamous cell carcinoma. Researchers will follow 116 patients starting cemiplimab in regular care, comparing disease control …
Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Can walking flush out hidden toxins? new study tests exercise against PFAS
Knowledge-focused Not yet recruitingThis study investigates whether different types of exercise can help middle-aged women reduce their body burden of PFAS (environmental chemicals) and improve muscle function. Participants will be assigned to either interval walking or high-intensity circuit training for six month…
Sponsor: Poznan University of Physical Education • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Blood tests could reveal hidden resistance in breast cancer
Knowledge-focused Not yet recruitingThis study observes people with a common type of advanced breast cancer (HR+/HER2-) who are already on standard hormone therapy. Researchers use simple blood tests to look for changes in the ESR1 gene, which can make the cancer stop responding to treatment. By tracking these muta…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Lab-Grown lung tumors could reveal why some drugs work and others fail
Knowledge-focused Not yet recruitingThis study takes leftover tumor samples from people with EGFR-mutant non-small cell lung cancer and grows them in the lab as cell cultures and organoids. Researchers will test different anti-EGFR drugs on these models to see which ones work best for each type of mutation and expl…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Exercise after breast cancer: which workout best boosts healing muscle signals?
Knowledge-focused Not yet recruitingThis pilot study looks at how different resistance training routines change levels of myokines—molecules released by muscles during exercise—in women who have finished breast cancer treatment. Participants will be assigned to one of three exercise regimens (conditioning, strength…
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Scientists probe tumor environment to predict drug resistance in stomach cancer
Knowledge-focused Not yet recruitingThis study investigates why some stomach cancers do not respond to a standard chemotherapy combination (FLOT) plus the immunotherapy drug durvalumab. Researchers will analyze tumor samples and blood from 250 patients with operable stomach or gastroesophageal junction cancer. By m…
Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Saliva test may reveal hidden spread of oral cancer
Knowledge-focused Not yet recruitingThis study investigates whether substances in saliva, specifically interleukin-6 levels and certain gene variations, can indicate whether oral cancer has spread to lymph nodes in the neck. Researchers will collect saliva samples from adults with oral squamous cell carcinoma befor…
Sponsor: University of Pavia • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Can a chemo combo without anthracyclines still beat breast cancer?
Knowledge-focused Not yet recruitingThis study looks at how well a chemotherapy and immunotherapy combination works for early triple-negative breast cancer when the usual anthracycline drugs are left out. The researchers are focusing on patients who cannot take anthracyclines due to previous treatment, older age, o…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
4D MRI scans could reveal hidden clues about heart disease and cancer
Knowledge-focused Not yet recruitingThis study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…
Sponsor: Ulsan University Hospital • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Scientists map cellular secrets of recurring colon polyps to prevent future cancer
Knowledge-focused Not yet recruitingThis study investigates why colorectal adenomas (precancerous polyps) sometimes return after being surgically removed. Researchers will collect tissue samples from 30 patients and use advanced genetic sequencing to compare polyps that recur with those that do not. The goal is to …
Sponsor: Zhongshan Hospital Xiamen University • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Real-World study eyes drug combo for tough prostate cancer
Knowledge-focused Not yet recruitingThis study observes how well a combination of two drugs, olaparib and abiraterone, works as a first treatment for men with metastatic castration-resistant prostate cancer who have already tried other hormone therapies. Researchers will track how long patients stay on the treatmen…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Blood test and AI team up to outsmart colon cancer recurrence
Knowledge-focused Not yet recruitingThis study explores whether combining artificial intelligence analysis of tumor tissue with special blood tests (liquid biopsy) can more accurately predict if colon cancer will return after surgery. Researchers will follow 400 adults with stage II or III colon cancer for up to fi…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Real-World data on colorectal cancer: what happens to patients over time?
Knowledge-focused Not yet recruitingThis study follows about 2000 people with colorectal cancer to track their health over time, including survival, disease progression, and side effects from treatments. Researchers aim to understand how the disease behaves in real-world settings, outside of controlled clinical tri…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Body clock check: a simple swab may guide immunotherapy timing for lung cancer
Knowledge-focused Not yet recruitingThis study explores whether a hair follicle or cheek swab can accurately measure a person's internal body clock (circadian rhythm) in patients with advanced lung cancer receiving immunotherapy. Researchers will use a new tool called TimeTeller to analyze gene activity from these …
Sponsor: Laura Longshaw • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Which intubation method works best for acromegaly patients?
Knowledge-focused Not yet recruitingThis study looks at how to safely place a breathing tube in people with acromegaly, a condition that can cause changes in the face and airway. It compares two methods: direct laryngoscopy and video laryngoscopy. The goal is to find which method gives a better view of the airway a…
Sponsor: Muzaffer GENCER • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC